UAE Cancer Congress by MCI TangenC

Under the patronage of

H.H. Sheikh Hamdan Bin Rashid Al Maktoum Deputy Ruler of Dubai, Minister of Finance and President of Dubai Health Authority

U E C NCER

CONGRESS 2012 11 - 13 OCTOBER 2012 InterContinental Festival City,Dubai, UAE

18 CPD CRED IT POINTS Accredited by Dubai Health A uthority

THE CONGRESS IS ACCREDITED WITH 25 ESMO-MORA CAT 1 POINTS

Stay Connected:

/uaecc2012 I

/uaecancercongress I

/uaecancercongress

www.uaecancercongress.ae Supported by

Platinum Sponsor

ONCOLOGY

Gold Sponsors

ONCOLOGY Putting progress into practice

Eisai MENA

Silver Sponsors

Congress Bag Sponsor

Official Journal

Support Sponsors

Congress Partner

Official News Distributor

Media Partners

ure eart

p r o g r a m

www.uaecancercongress.ae

Congress Secretariat: MCI Middle East, United Arab Emirates, Tel: +971 4 311 6300, Fax: +971 4 311 6301, E-mail: uaecancercongress@mci-group.com

His Highness Sheikh Khalifa Bin Zayed Al Nahyan President of the U.A.E

www.uaecancercongress.ae

His Highness Sheikh Mohammed Bin Rashid Al Maktoum Vice President, Prime Minister and Ruler of Dubai

www.uaecancercongress.ae

His Highness Sheikh Hamdan Bin Rashid Al Maktoum Deputy Ruler of Dubai, Minister of Finance, UAE President of Dubai Health Authority

www.uaecancercongress.ae

Table of Contents Welcome Message ............................................................. 06 Organising Committee ........................................................ 07-08 Scientific Committee ........................................................... 09-11 Venue & Exhibition Layout .................................................. 12-13 Programme at a Glance ........................................................14 Sceintific Program ............................................................... 16-24 Faculty Profile ................................................................... 26-74 Best Abstracts ................................................................... 76-83 Experience Dubai .............................................................. 86-89 Acknowledgement .............................................................. 90

www.uaecancercongress.ae

Welcome Message

Dear Colleagues, First you start with an idea, a dream and then you place the foundation upon which to build that dream and then continue to build and watch it grow into something above and beyond your expectation. This has been the journey of the UAE Cancer Congress. We started of with a small congress in 2009 with the hope of promoting a multidisciplinary approach to the management of individuals with cancer. We’ve watched the congress not only grow but develop into something that the region can truly be proud of. Last year was without a doubt a successful year for the UAE Cancer Congress. It attracted approximately 700 delegates not only from the gulf region but also from the Asia pacific and European regions. It boasted a fantastic scientific program that had something for everyone. And now with 2012 upon us, our whole team welcomes you back to the UAE Cancer Congress 2012. This year we continue our theme of “Promoting Excellence in Oncology” with the principal goal of promoting multidisciplinary care of patients suffering from cancer. Our program this year boasts top regional and international faculty who have come together to bring you a scientific program that you will truly enjoy. Our program will have didactic lectures, debates, challenging case presentations and oral presentations of the best research submitted from the region. We continue to develop our surgical oncology workshops making them as hands on and interactive as possible. The goals of the UAE Cancer Congress have stayed the same since its conception principally to bring the best academic congress to the region as well as support research. Last year, we had the first research grant awarded. We continue this year with the same goals and will continue to support education, research and training and to that end numerous best abstract awards and travel grants will be made available. Abstracts and grants submitted will also undergo a careful review process from our fantastic scientific committee. This year we have also joined hands with the journal of cancer which will afford the opportunity for publication of the top abstracts submitted. Overall this year will, I am sure, prove to be an engaging experience for all attendees and will afford plenty of networking opportunities. Please visit the website and follow our

/uaecc2012 or like us on

/uaecancercongress to be

kept abreast of upcoming exciting updates.

Best Regards, Shaheenah Dawood Congress President Medical Oncologist Dubai, UAE

www.uaecancercongress.ae

Organizing Committee

Shaheenah Dawood President of the Congress Dubai Hospital UAE

Aladdin Maarraoui, MD, FACP Clinical Associate Professor Gulf Medical University Consultant and Chief of Hematology/Oncology Mafraq Hospital UAE

Alex Chang , MD CEO & Medical Director John Hopkins Singapore International Medical Centre Singapore

Aly Abdel Razek Executive Director Gulf International Cancer Center Chief of Radiation Oncology UAE

Alya Al Mazrouei Consultant Surgeon General Surgery Department Rashid Hospital Dubai, UAE

Bassim Al Bahrani Sr. Consultant Medical Oncologist & Head of Medical Oncology Department National Oncology Cancer Royal Hospital Oman

Bhawna Sirohi Artemis Health Institute India

Dia Trad, MD Tawam Hospital (affiliated with Johns Hopkins) Al Ain, UAE

Dhairyasheel Savant Consultant Surgical Oncologist Reconstructive & Microvascular Surgeon India

Faisal Badri, M.D. F.R.C.S. Consultant & Head of General Surgery Department Rashid Hospital Dubai, UAE

www.uaecancercongress.ae

Organizing Committee

Faisal Badri, M.D. F.R.C.S Consultant & Head of General Surgery Department Rashid Hospital Dubai UAE

Hamdy A. Azim Prof. of Clinical Oncology Cairo University Chairman of Cairo Oncology Center (Cairo Cure) Egypt

Gabriel Ionescu Senior Consultant Chief Division Pediatric Surgery at Tawam Hospital UAE

Mikael Hartman Consultant, Breast and Trauma Surgery, NUH, Assistant Professor, Department of Epidemiology and Public Health, NUS Adjunct Staff, Department of Medical Epidemiology, Karolinska Institute, Sweden Singapore

Vineet Gupta Diplomate American Board (Int Medicine, Hematology, Med.Oncology) Group Medical Director Health Care Global Enterprises Ltd India

Gilberto de Lima Lopes, Jr Senior Consultant in Medical Oncology, Assistant Director for Clinical Research, Assistant Professor of Oncology Johns Hopkins International Medical Centre, Singapore

Sana Al-Sukhun Diplomat American Board of Internal Medicine/Medical Oncology & Hematology, Assistant Professor of Medicine, Faculty of Medicine University of Jordan Jordan

Waleed Hassen Chief of Pediatric Surgery Tawam Hospital Al Ain UAE

www.uaecancercongress.ae

Scientific Committee

Alya Al Mazrouei Consultant Surgeon General Surgery Department Rashid hospital, Dubai UAE

Ana Maria Gonzalez Angulo, MD Associate Professor Dept. of Breast Medical Oncology Dept. of Systems Biology The University of Texas M. D. Anderson Cancer Center USA

Axel Grothey Professor of Oncology & Consultant Mayo Clinic Cancer Center USA

Ayman Allam Consultant, Palliative/Medical Oncology Al Amal Hospital

Azza Adel Hassan, MD Program Director, Palliative Care Program Consultant, Medical Oncology Assistant Professor of Clinical Medicine, Weill Cornell Hamad Medical Corporation Qatar

Belal El-Hawwari Consultant Radiation Oncologist Section Head, Radiotherapy Departement King Hussien Medical City Jordan

C S Pramesh, MS, FRCS Associate Professor, Thoracic Surgery, Department of Surgical Oncology Convener, Thoracic Oncology Disease Management group Tata Memorial Centre India

Dhairyasheel Savant Consultant Surgical Oncologist Reconstructive & Microvascular Surgeon India

Faisal Badri, M.D. F.R.C.S. Consultant & Head of General Surgery Department Rashid Hospital Dubai UAE

Hamdy A. Azim Prof. of Clinical Oncology Cairo University Chairman of Cairo Oncology Center (Cairo Cure) Egypt

Hassan Jaafar Medical Consultant Tawam Hospital (affiliated with Johns Hopkins) Al Ain UAE

George Blumenschein, MD Associate Professor Thoracic/Head & Neck Med Onc, The University of Texas MD Anderson Cancer USA

www.uaecancercongress.ae

Scientific Committee

Hanan Hamed, MD Cairo Egypt

Heba El-Zawahry M.D Prof. Medical Oncology National Cancer institute Egypt

Kakil Ibrahim Rasul CABM, FRCP Edin, ESMO Associate Prof. of Clinical Medicine, Weill Cornell Medical College in Qatar, Senior Consultant Haem/Oncology

Maroun Khoury, MD Consultant Hematology / Oncology Dubai UAE

Mufid El Mistiri, MDs Consultant Medical Oncology Director of Qatar Cancer Registry, NCCCR, Assistant Professor of Clinical Medicine,Weill Cornell Medical College Qatar

Mohd Ussama Al Homsi Hamad Medical Corporation Doha Qatar

Nagi S. El Saghir, MD, FACP Professor of Clinical Medicine Director, Breast Center of Excellence NK Basile Cancer Institute American University of Beirut Medical Center, Beirut Lebanon

Pankaj Chaturvedi, MS FAIS FICS FACS MNAMS Associate Professor, Head and Neck Department Tata Memorial Hospital, India

Hesham El Ghazaly Professor of Clinical Oncology Ain Shams University Egypt

Michael L. Kendrick, M.D. Chair, Division of GI and General Surgery, Associate Professor of Surgery Mayo Clinic College of Medicine, USA

Muhammad Ali Chaudhry, MD Medical Director Tawam Molecular Imaging Center, UAE Clinical Assistant Professor of Radiology Johns Hopkins University School of Medicine USA

Pedro T. Ramirez The University of Texas MD Anderson Cancer Center USA

www.uaecancercongress.ae

Scientific Committee

Rabab Gaafar, MD Prof Medical Oncology NCI, Cairo University

Sami Ahmad Khatib, MD Consultant Clinical Oncologist Amman Jordan

Shona Nag Jehangir Hospital India

Rebecca Dent Consultant Dept of Medical Oncology National Cancer Centre Singapore

RenĂŠ Adam Centre HĂŠpato-Biliaire Paul Brousse Hospital France

Shah Numani American Hospital Dubai UAE

Shailesh V. Shrikhande Associate Professor of Surgery, GI & HPB Surgical Oncology, Tata Memorial Centre, India

Sudeep Gupta, MD, DM Professor of Medical Oncology Tata Memorial Hospital India

Vineet Gupta, MD Diplomate American Board (Int Medicine, Hematology, Med.Oncology) Group Medical Director, Health Care Global Enterprises Ltd India

www.uaecancercongress.ae

entatio

Pres Poster

3x3

Reserve

3x3

HAMS d S

Pillar

3x3 3x3

Oncology Nursing Society

3x3

BGICS

3x3

LILLY

Boehringer Ingelhein 3x3

9 5x3

SanoďŹ

5x3

ENTRANCE

5 3x3

Sirtex

5x3

Roche

3x3

New Bridge

MSD

AstraZeneca

NeoBiocon Pierre Fabre Biologix

ENTRANCE

3x3

Nestle

4x3

3x3

Coffee Station

6x3

3x3

Janssen

3x3

Molecular Imaging Center

8 Tawam

AMGEN

BMS

Atlas Medical

ENTRANCE

6x3

GSK

ENTRANCE

EMEACR Pure Heart

6x3

Actavis

5x3

EISAI MENA

Novartis

ENTRANCE

Plenary Room

ENTRANCE

Venue & Exhibition Layout

www.uaecancercongress.ae

Entrance

Media Desk

Entrance

Breakout Sessions Al Baraha 1 - 3

From th e Lobb y

www.uaecancercongress.ae 18:00

17:00

16:00

15:00

14:00

13:00

12:00

11:00

10:00

09:00

08:00

07:00

Day 1

Registration - Al Ras 1 & 2 Foyer ONS Session - Amwaj 2 Exhibition & Coffee Breaks - Al Ras 1 & 2

Meet The Professor Session I Al Ras 3

Al Ras 3

Breast Cancer Session I

Lunch Break

Thursday 11th Oct 2012

Opening Ceremony

Publication Workshop

Al Baraha 1 Lung Cancer Session

Al Ras 3

Nutrition Workshop Amwaj 1

Day 2

Registration - Al Ras 1 & 2 Foyer Exhibition & Coffee Breaks - Al Ras 1 & 2

Cancer Imaging Session Al Baraha 3 Gyne Oncology Session II - Al Baraha 1

Gyne Oncology Session I Al Baraha 1

Lunch & Prayer Break

Head & Neck Oncology Session I Al Majlis

Breast Cancer Session II Al Ras 3

Friday 12th Oct 2012

Breast Cancer Session III - Al Ras 3 GI Surgical Oncology Workshop Al Baraha 2

Palliative Care Workshop Amwaj 2

ONS Session Amwaj 2

Registration

Day 3

Exhibition & Coffee Breaks GI Session

GI Surgical Session with Rene Adam Al Baraha 2

Al Baraha 2 Breast Surgical Oncology Workshop Al Ras 3 Head & Neck Oncology Session II

Al Baraha 1

Lunch Break

Saturday 13th Oct 2012

ONS Session - Amwaj 2

18:00

17:00

16:00

15:00

14:00

13:00

12:00

11:00

10:00

09:00

08:00

07:00

Programme at a Glance

www.uaecancercongress.ae

Scientific Programme Thursday, 11th October 2012 07:00 – 09:00

Registration & Coffee

07:30 – 17:00

ONS Session - Amwaj 2

09:00 – 12:00

Publication Workshop - Al Baraha 1

09:00 – 14:00

Nutrition Workshop - Amwaj 1

11:30 – 12:00

Opening Ceremony - Al Ras 3

Lung Cancer Session - Al Ras 3

Session Chairs: Amgad El Sherif, UAE

08:00 - 08:30

Screening in Lung Cancer

Abdul Rahman Jazieh, KSA

08:30 - 09:00

Controversies in Management of early Lung Cancer

C S Pramesh, India

09:00 - 09:30

Controversies in Radiation Therapy: Treatment options for Medically Unfit Patients with early NSCLC

Joost Nuyttens

09:30 - 10:30

Controversies in Chemotherapy

Personalized Therapy in NSCLC – Past, Present and Future

George Blumenschein, USA

New Algorithm of Treatment in Advanced Non Small Cell Lung cancer - Is there still room for Improvement?

Mehdi Shahidi, UK

10:30 - 11:30

Case Discussions

Moderator – Kumar Prabhash, India Panel Members: Amgad El Sherif Nasser Al-Dhaibani, UAE Maroun Khoury, UAE Joost Nuyttens George Blumenschein, USA C S Pramesh, India

12:00 - 13:00

Lunch Break

Breast Cancer Session I - Al Ras 3

Breast Session 1: Trials and Tribulations of Metastatic Breast Cancer Chairs: Rebecca Dent, Singapore I Ahmed Saadeddin

13:00 -13:20

How Should we Overcome Endocrine Resistance in 2012?

C S Pramesh, India

Maroun Khoury, UAE

Jose Baselga, USA

13:20 -13:40 Case Presentation: A 35 Year Old Pre Menopausal with Hormone Receptor Hamdy Abdul Azim, Egypt Positive, HER2 Negative Metastatic Breast Cancer. What are the Burning Issues? 13:40 – 14:00 Having HER2 Positive Breast Cancer: More Options than Answers? Paul Ellis, UK 14:00 – 14:20

Case Presentation: How to Approach a Woman with Metastatic Triple Negative Breast Cancer. Is there Anything Novel in 2012?

Sudeep Gupta, India

14:20 -14:40 Novel Systemic Approaches to Management of Brain Metastases: Cliff Hudis, USA Are We There Yet?

www.uaecancercongress.ae

Scientific Programme 14:40 – 15:00

Can MBC be Cured in 2012?

15:00 – 15:20

Coffee Break

Omal Khair Abulkhair, KSA

Breast Session 2: Controversies with Neoadjuvant Treatment of Breast Cancer (A Joint Symposium with the BGICC Group) Chairs: Salim Chaib Rassou, UAE I Houriya Kazim, UAE 15:20 – 15:40 Defining the Role of the Radiologist in the Multidisciplinary Management of a Naglaa Abd El Razek, Egypt Woman Receiving Pre Operative Chemotherapy 15:40 – 16:00 How Best to Assess the Axilla in a Woman Receiving Pre operative Mehra Golshan, TBvA Chemotherapy: Is There a Right Way? 16:00 – 16:20 Extending Indications of BCS for Locally Advanced Breast Cancer Omar Zakaria, Egypt 16:20 – 16:30 16:30 – 16:40

Debate: Should all Women Receive Pre operative Chemotherapy Yes: Ana Maria Gonzalez Angulo, USA No: Cliff Hudis, USA

16:40 – 17:10 Case Presentation: Tracing the Multidisciplinary Management of a Woman Hesham El Ghazaly, Egypt Receiving Pre Operative Chemotherapy 17:30 – 19:00 Meet the Professor Session (Limit 50 People) Chairs: Sudeep Gupta, India I Norbit Dreier, UAE Theme: What’s New and Groovy in the Management of MBC? 17:30 – 18:00 Is Chemotherapy a thing of the Past for Hormone Receptor Positive MBC? Jose Baselga, USA Interactive Patient Case Study 18:00 – 18:30 Trastuzumab, Pertuzumab, TDMI or Lapatinib: When, Where and How? Cliff Hudis, USA Interactive Patient Case Study 18:30 – 19:00 Heavily Pre Treated Patient with MBC: What is new on the Horizon? Edith Perez, USA Interactive Patient Case Study

Friday, 12th October, 2012 07:00 – 09:00

Registration & Coffee

08:00 - 12:00 Palliative Care Workshop - Amwaj 2

Cancer Imaging Session - Al Baraha 3 Head and Neck Cancer Session

08:00 - 08:20 08:20 - 09:00

Role of Imaging: Radiotherapy Perspective

Nasser Al-Dhaibani, UAE

Role of PETCT

Mohei Abouzied, UAE

09:00 - 09:40

Multifunctional MRI: Applications and Challenges in Breast, Head & Neck and Pelvic Oncology

Abhishek Mahajan, India

09:40 - 14:00

Breast Cancer Session

09:40 - 10:20

Establishing a Mammography Program: Lessons from Egypt

Dorria Salem, Egypt

10:20 - 11:00

Screening Mammography

Seema Kembhavi, India

11:00 - 11:40

Role of Sonography

10:00 - 10:20

MR Mammography

www.uaecancercongress.ae

Seema Kembhavi, India Atif Zaheer, USA 17

Scientific Programme 11:40 - 12:40

Lunch & Prayer Break

12:40 - 13:20

MR Mammography

13:20 - 14:00

Role of PET/CT

14:00 - 15:00

PETCT/Coloretal Session

14:00 - 14:20

PETCT Role in Radiotherapy Planning

14:20 - 15:00

Rectal Cancer Staging Imaging

15:00 - 15:20

Coffee Break

15:20 - 17:00

Pelvic Cancers Session

15:20 - 16:00

Cervical Cancer Staging: MRI

16:00 - 16:40

MRI of the Prostate

16:40 - 17:00

Role of PETCT in Cervical Cancer Staging

Gynecologic Oncology Session - Al Baraha 1

Atif Zaheer, USA Muhammad Ali Chaudhry, UAE

Maryam Aslani, UAE

Atif Zaheer, USA

Seema Kembhavi, India

Atif Zaheer, USA Muhammad Ali Chaudhry, UAE

07:50 – 08:00 Introduction Nicole Fleming (USA)

Updates and Controversies in Ovarian Cancer Moderator: Nicole Fleming (USA)

08:00 – 08:25 Novel Targeted Therapies in Ovarian Cancer Speaker: Sana Al – Sukhun, MD, MSc. (Jordan) Discussion (5 min) 08:25 – 08:55 Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: Is this the New Standard of Care? PRO: Shona Nag (India) CON: Luis Chiva (Spain) Discussion (5 min) 08:55 – 09:15 Secondary Cytoreductive Surgery in Ovarian Cancer Speaker: Francesco Raspagliesi (Italy) Discussion (5 min) 09:15 – 09:45 Updates on Medical Management of Recurrent Ovarian Cancer Speaker: Antonio Gonzalez Martin (Spain) Discussion (5 min) 09:45 – 10:15 Current Management of Rare Ovarian Tumors Speaker: Sudeep Gupta (India) Discussion (5 min) 10:15 – 10:30

Coffee Break

Emerging Therapies in Endometrial Cancer Moderator: Antonio Gonzalez Martin (Spain) 10:30 – 10:55 The Role of Lymphadenectomy and Lymphatic Mapping in Endometrial Cancer Speaker: Francesco Raspagliesi (Italy) Discussion (5 min) 10:55 – 11:20 Updates on Medical Management of Advanced/Recurrent Endometrial Cancer Speaker: Sana Al-Sukhun, MD, MSc. (Jordan) Discussion (5 min) 18

www.uaecancercongress.ae

Scientific Programme 11:20 – 11:50 Role of Tomotherapy in Treatment of Gynecologic Malignancies Speaker: Luis Schiappacasse (France) Discussion (5 min) 11:50 – 13:00

Lunch & Prayer Break

13:00 – 15:00 Surgical Video Symposium Moderators: Nicole Fleming (USA) Luis Chiva (Spain)

Role of Minimally Invasive Surgery in Gynecologic Oncology Speaker: Nicole Fleming (USA)

Surgical Video Session (15 mins/video) r Surgical Tips in Upper Abdominal Procedures (Luis Chiva) r Retroperitoneal Debulking and Vascular Complications (Luis Chiva) r Nervous and Lymphatic Anatomy in Para – Aortic Lymphadenectomy (Francesco Raspagliesi) r Robotic Radical Trachelectomy for Cervical Cancer (Nicole Fleming) r Lymphatic Mapping and Sentinel Lymph Node Biopsy (TBD) Video Submissions Award Video Winner #1 15:00 – 15:15

Coffee Break

15:15 – 16:15 Tumor Board Moderator: Nicole Fleming (USA) Panelists: Luis Chiva (Spain) Sudeep Gupta (India) Sana Al – Shukun (Jordan) Luis Schiappacasse (France) Clinical Update in Cervical Cancer Moderator: Sudeep Gutpa, India 16:15 – 16:35 Early – Stage Cervical Cancer: Updates on Fertility Preservation Speaker: Nicole Fleming (USA) Discussion (5 min) 16:35 – 17:00 Treatment of Locally Advanced Cervical Cancer Speaker: Antonio Gonzalez Martin (Spain) Discussion (5 min) 17:00 – 17:30 Use of Targeted Agents in Cervical Cancer Speaker: Shona Nag (India) Discussion (5 min) 17:30 – 17:45

Conclusion Nicole Fleming (USA)

www.uaecancercongress.ae

Scientific Programme

Breast Cancer Session II - Al Ras 3

09:00 -09:30

Interactive Patient Case Presentation (Brain Metastases) Panel Members: Meteb Al-Foheidi, UAE Salim Chaib Rassou, UAE Norbit Dreier, UAE Nouri Benini, UAE

Breast Session 3: The Past, Present and Future of Breast Cancer Treatment Chairs: Meteb Al-Foheidi, UAE I Irfan Ul Haq I Salim Chaib Rassou, UAE

Rebecca Dent, Singapore

09:30 – 10:00 The Triumphs and Pitfalls of 2011/2012 David Miles, UK 10:00 – 10:20 Advances in Breast Cancer Biology: What we have Learnt , What we Know, Jose Baselga, USA What we Look Forward to 10:20 -10:50 The Treatment Cut Off for FISH HER2 Levels: The Confusion Stops Here! Edith Perez, USA 10:50 -11:10 Molecular Assessment and Patient Selection for Adjuvant Therapy: Can we Ana Maria Gonzalez Avoid Chemotherapy? Angulo, USA 11:10 – 11:30 What is the Role of Post Mastectomy Radiation among Women with 1 to 3 Aly Abdel Razek, UAE Positive Lymph Nodes in 2012 12:00 – 12:30 Lunch & Prayer Break 12:30 - 13:30

Interactive Patient Case Discussion: Moderator, Vineet Gupta Panel Members: Aly Abdel Razek, UAE Bhawna Sirohi, India Edith Perez, USA Hamdy Abdul Azim, Egypt Jose Baselga, USA Paul Ellis, UK Shah Numani, UAE Case 1: Endocrine Resistant Breast Cancer Case 2: Oncotype DX for Node Positive Breast Cancer: Are We There Yet Case 3: Triple Negative Breast Cancer

Breast Session 4: Controversies and Debates of 2012 Chairs: Vineet Gupta, India I Nouri Benini, UAE I Ramanujam Singarachari, UAE 13:30 -13:50 Incorporating Bisphosphonates among Women with Early Stage Breast Cancer Yes: Nagi El Saghir, Lebanon No: Sudeep Gupta, India

13:50 - 14:10

Role of Antiangiogenic Agents: Where Did We Go Wrong?

14:10 -14:30 14:30 – 14:50

Case Debate: 45 Years Old Pre Menopausal Woman with Grade II T1a N0M0 HER2 Positive, Hormone Receptor Positive Breast Cancer There is a Role of Adjuvant Trastuzumab: Jose Baselga, USA There is no Role for Adjuvant Trastuzumab: David Miles, UK Dual HER2 Blocking in a Woman with HER2 Positive MBC: Do We Need to add Chemotherapy? Yes: Edith Perez, USA No: Paul Ellis, UK

www.uaecancercongress.ae

David Miles, UK

Scientific Programme 14:50 – 15:10

Case Debate: 35 Years Old Pre Menopausal Women with a Grade III T2N0M0 Triple Receptor Negative Breast Cancer: Are Anthracylines Necessary? Yes: Vineet Gupta, India No: Rebecca Dent, Singapore

15:10 – 15:30

Case Debate: 55 Years Post Menopausal Woman with pT2N1M0 IDC, ER/PR Positive, HER2 Negative. Had Surgery, Adjuvant Chemotherapy and Adjuvant XRT. Needs to be Started on Adjuvant Endocrine Therapy. Which Agent First? Is Longer Better? Aromatase Inhibitor First Tamoxifen followed by Aromatase Inhibitor

Ana Maria Gonzalez, USA Nagi El Saghir, Lebanon

15:30 – 15:50

Forgoing ALND in Sentinel Node Positive Women: Should we be more Cautious?

S V Deo, India

15:50 – 16:10

Case Debate: 65 years Old Lady with Newly Diagnosed MBC. ER/PR Positive. HER2 Negative. Has Radiological Evidence of Extensive Bone Metastases The Case for Denosumab: Hamdy Abdul Azim, Egypt The Case for Zoledronic Ascid: Bhawna Sirohi, India

16:10 – 16:30

Biopsy of a Patient with MBC: When to Order and How to Integrate Results

Head & Neck Session I - Al Majlis

12:00 - 13:00

Lunch and Poster Viewing Judges r Ravinder Deo, India r Chirag Shah, India r Soma Sundaram, Russia r Sankar Srinivasan, India r Biswajit Bhattacharya, Bangladesh

13:00 - 13:15

Welcome Speech by Program Chairperson Pankaj Chaturvedi, India

13:15 - 13:45

Pearls of Wisdom Chairpersons: Sangita Bhandari, Nepal I Ravinder Deo, India r How to Save the Recurrent Laryngeal Nerve and Superior Laryngeal Nerve during Thyroid Surgery - Balazs B Lorincz, Germany r How do I Save the Important Nerves during Surgery (Facial and Spinal Accessory) Dhairyasheel Savant, India r How to Manage the Side effect RT/CT in HNSCC - Arif Jamshed, Pakistan

13:45 - 14:00

Q&A

14:00 - 14:40

Part - I: Important Issues in the Management of HNSCC Chairpersons: Raghav Dwivedi, UK I Ajit Veniyoor, India r Precision Medicine Approaches in the Curative and Palliative Treatment of Head and Neck Cancer - Tanguy Seiwert, USA r What is Best Management of Neck in T1/2 N0 Patients Neck Dissection or Observation? - Gauri Pantvaidya, India r Management of Laryngeal Fold Paralysis - Gayle Woodson, USA r Laser Surgery for locally Advanced Lesions in Larynx and Pharynx - Cesare Piazza, Italy

14:40 - 15:00

Q&A

15:00 - 15:15

Coffee Break

Paul Ellis, UK

15:15 - 16:15 PART – II: Important Issues in the Management of HNSCC Chairpersons: Shishir Shetty, India I Vedant Kabra, India I Hussain Abdul Rahman, UAE r Transoral Robotic surgery - Challenges and Opportunities - Cyrus Kerawala, UK r Management of Nutrition during treatment of HNSCC - Shaesta Mehta, India r Optimal Imaging in HNSCC - Shashikant Juvekar, India r Prevention and Screening of HNSCC - Vishal Rao, India

www.uaecancercongress.ae

Scientific Programme 16:15 - 17:15

Chemotherapy in Head and Neck Cancers Revisted Moderator: Chetna Bakshi I Sanker Srinivasan, India r Palliative Chemotherapy - When, What, How? - Sandeep Goyle, India r Induction Chemotherapy - What is the Current Evidence? - Ashish Bakshi, India r Anaplastic/Medullary Carcinoma of Thyroid - Role of Chemotherapy - Shailesh Bondarde, India r Metronomic Therapy - Does it have a Role? - Nirmal Raut, India

GI Surgical Oncology Workshop Session - Al Baraha 2

Chairs: Harit Chaturvedi, India I Jorg Kleeff, Germany 13:00 - 13:20

Laparoscopic Pancreatic Surgery: Indications and Outcomes

Michael Kendrick, USA

13:30 - 13:50

Evidence Based Surgical Management of Pancreatic Tumors

Shailesh V. Shrikhande, India

14:00 - 15:00

Master Videos r SMA First Technique r Laparoscopic Whipple Resection r Right Hepatectomy r VATS Esophagectomy r 2 Field Esophagectomy

Shailesh V. Shrikhande, India Michael Kendrick, USA Mahesh Goel, India K. George, India Jorg Kleeff, Germany

15:00 – 15:15

Coffee Break

15:15 - 17:15

Interactive Case Based Discussion Chairs: Michael Kendrick, USA I Harit Chaturvedi, India

r r r r

12:30 - 14:30

ONS Session - Amwaj 2

Neoadjuvant Approaches in GI Cancers Cystic Tumors of the Pancreas Emerging Multimodality Approach in HCC mCRC: What’s New 2012

Bhawna Sirohi, India Shailesh V. Shrikhande, India Mahesh Goel, India TBA

saturday 13th October, 2012 08:00 – 13:00

ONS Session - Amwaj 2

GI Session - Al Baraha 2

07:00 – 09:00

Registration & Coffee

07:30 - 09:00 Meet the Professor Session: René Adam, France Moderators: Shailesh V. Shrikhande, India I Bhawna Sirohi, India GI Session I: Hot Topics of 2012 Chairpersons: Eric Van Cutsem, Belgium I Norbit Dreier, UAE

09:00 - 09:20

The Positive, the Negative and the Maybe of 2011 and 2012

Marc Peters

09:25 - 09:45

Gene Expression Profiling for Colon Cancer: Is it Ready for Prime Time Use?

Axel Grothey, USA

09:50 - 10:10

The Flop Side of Adjuvant Targeted Therapy. Is There a Way Forward?

Marc Peters

10:15 10:40

Debate 1: Xeloda or Infusional 5FU for Metastatic Colon Cancer No Difference: Ranga Rao, India There is a Difference: Axel Grothey, USA

10:40 - 10:55

Coffee Break

www.uaecancercongress.ae

Scientific Programme 11:00 - 11:20

What’s New on the Horizon for Metastatic Colon Cancer?

11:25 - 11:50

Debate 2: A 55-year old gentleman presenting with a Primary Lesion in the Colon Non-Obstructing growth but Occasional Bleeding per Rectum. Staging reveals four Liver Metastatic Lesions that are considered to be Borderline Resectable Surgery first: René Adam, France Chemotherapy first: Norbit Dreier, UAE

11:55 - 12:20 12:20 - 13:00

Eric Van Cutsem, Belgium

Debate 3: Is Post Operative Chemotherapy Required in Patients with Rectal Cancer attaining a pCR Yes: Eric Van Cutsem, Belgium No: Bhawna Sirohi, India Lunch Break

GI Session 2 Chairpersons: Ranga Rao, India I Mahesh Goel, India 13:00 - 13:20

Stop and go or Continuous Bevacizumab: Is There a Right Way?

Axel Grothey, USA

13:25 - 13:45

The Ideal Chemotherapy Backbone to Biologics: Do we Know What it is? Marc Peters

13:50 - 14:10

Are all KRAS Mutations the Same

Eric Van Cutsem, Belgium

14:15 - 14:35

Neoadjuvant Radiotherapy in Low Rectal Cancer

Syed Mansoor Hasnain, UAE

14:40 - 15:00

Management of Peritoneal Metastases in CRC

Faheez Mohamed, UK

15:00 - 15:15

Coffee Break

15:20 - 16:20

Interactive Case Based Session Moderator: Marwan Khoury, UAE Panel Members: Axel Grothey, USA Eric Van Cutsem, Belgium Marc Peters Michael Kendrick, USA Shailesh Shrikhande, India René Adam, France Case 1: KRAS Wild Type Metastatic Colorectal Cancer Case 2: KRAS Mutant Metastatic Colorectal Cancer Case 3: Stage III Colorectal Cancer Case 4: Colorectal Cancer and Liver Metastases

Breast Surgical Oncology Workshop Session - Al Ras 3

08:25 – 08:30

Introduction and Overview

08:30 – 09:15

Video Session: Ductoscopy Sentinel Node Biopsy in Breast Cancer Surgery Intraoperative Radiotherapy in BCT Oncoplastic Breast Surgery LD Flap Reconstruction following MRM

Session II

09:20 – 09:35

Oncologic Considerations in Breast Reconstruction following BCT/MRM

Dhairyasheel Savant, India

Session I

www.uaecancercongress.ae

Vinay Deshmane, India TBA Sanjay Sharma, India Vinay Deshmane, India Dhairyasheel Savant, India

Dhairyasheel Savant, India 23

Scientific Programme

09:35 – 09:50

Breast Cancer Surgery: What’s Being Discussed at the Major Meetings

Vinay Deshmane, India

09:50 – 10:00

Coffee Break

Session III

10:00 – 12:00 12:00 – 13:00

Case Capsules and Discussion: Cases Covering Gamut from Non Palpable to Early to LABC to Advanced and Metastatic Moderator: Sanjay Sharma, India Panelists: Faraz Khan, Medical Oncologist, UAE Houriya Khazim, Breast Surgeon, UAE Seema Kembavi, Imaging, India Salim Chaib Rassou, Radiation, UAE Vinay Deshmane, Surgeon, India

Session IV

13:00 – 13:45

Case Discussion - Surgical Unit, Dubai Hospital

13:45 – 14:00

Concluding Remarks and Summation

Head & Neck Session II - Al Baraha 1

09:00 - 10:00

What is New in Head and Neck Cancers Moderators: Suraj Pawar, India I Vedant Kabra, India

r r r r

10:00 - 10:45

Grand Debate - Is Chemo-Radiotherapy the Best Organ Preservation Strategy for HNSCC? Moderators: Arif Jamshed, Radiation Oncologist, Pakistan I Tanguy Seiwert, USA

r For - Kumar Prabhash, Medical Oncologist, India (15 mins) r Against -Vedang Murthy, Radiation Oncologist, India (15 mins)

10:30 - 10:45

Q&A

10:45 - 11:00

Coffee Break

11:00 - 12:00

Panel on Thyroid Cancer Moderator: Devendra Chaukar, Surgeon, India

Panelists: r Vikram Sanghvi, Surgical Oncologist, India r Sharmistha Gupta, Radiologist, UAE r Dauran Adilbay, Surgeon, Kazakhstan r Mandar Deshpande, Surgeon, India r Aly Abdel Razek, Radiation Oncologist, UAE r Gouri Pantvaidya, Surgeon, India r Nilesh Lok, Medical Oncologist, India

12:00 - 13:00

Panel on Challenging Problems in Management of HNSCC Moderator: Pankaj Chaturvedi, India

Panelists: r SVS Deo, Surgeon, India r Tarini Sahoo, Medical Oncologist, India r Shashikant Juvekar, India r Andrei Karpenko, Surgeon, Russia r Deepak Sarin, Surgical Oncologist, India r Salim Chaib Rassou, Radiation Oncologist, UAE r Jamil Hyder, Surgeon, Oman r Vanita Noronha, Medical Oncologist, India

Lunch Break

Surgery - K A Pathak, Canada Radiotherapy - Namrata Satyapal, Oman Chemotherapy - Tom Robbins, USA Chemoprevention - Nagao Toru, Japan

www.uaecancercongress.ae

Faculty Profile ONS Workshop

Mary Thomas, RN MS AOCN Hematology Clinical Nurse Specialist VA Palo Alto Health Care System, California, USA

Mary Laudon Thomas is the hematology clinical nurse specialist in at the Veterans Affairs Medical Center in Palo Alto, California and is also an Associate Clinical Professor in the School of Nursing at the University of California, San Francisco. She obtained her Bachelor of Science in Nursing Degree from the University of Wisconsin and her Master of Science Degree from the University of California, San Francisco, specializing in Oncology Nursing. She is an Advanced Certified Oncology Nurse. Ms. Thomas is a member of the Nurse Advisory Board of the International MDS Foundation, and is active in the Eastern Cooperative Oncology Group, where she is a member of the Nursing, Symptom Management, and Leukemia Committees. She has developed the quality of life and geriatric assessment component of a clinical trial treating AML in the elderly for ECOG and a quality of life section for a CLL treatment protocol submitted for approval. Ms. Thomas has been a member of the Oncology Nursing Society for almost 30 years. She has reviewed abstracts for the annual congress and is a member of the planning committee for the Regional Hematology Conferences for nurses in the U.S. Ms. Thomas is a representative of the VA Office of Nursing Service Advanced Practice Nurse Advisory Group where she co-chairs the planning committee for the 2013 VA APN Conference and a member of the VA Office of Nursing Service Evidence Based Practice Goal Group. She has presented to patients, nurses, physicians and the community on local, national and international levels.

Jean Ridgeway, RN APN NPC MSN AOCN Nurse Practitioner University of Chicago, Illinois, USA

Jean Ridgeway is an Advanced Practice Nurse/Nurse Practitioner at the University of Chicago Medical Center in Chicago, Illinois, USA. She works exclusively with the adult malignant haematology and stem cell transplant programs in the outpatient setting. She also teaches both nationally in the USA and internationally to nurses about leukaemiaâ&#x20AC;&#x2122;s, lymphoma, multiple myeloma, myelodysplastic syndromes and stem cell transplant. She has authored various articles and book chapters on these topics. She lives in the city of Chicago where she is an adjunct faculty at the University of Illinois College of Nursing and Loyola University College of Nursing.

www.uaecancercongress.ae

Faculty Profile Nutrition Workshop

Clare Shaw, PhD RD Consultant Dietitian The Royal Marsden NHS Foundation Trust, UK

Clare is Consultant Dietician at The Royal Marsden NHS Foundation Trust and has specialised in working with oncology patients for over 20 years. Her work has included advising patients with different cancer diagnoses including head and neck, gastrointestinal and breast cancer. More recent work includes working with patients who have late gastrointestinal effects following treatment for cancer in a specialised outpatient setting. Outside her work at The Royal Marsden she is on the Clinical Advisory Board for Macmillan, a national UK cancer charity. She was also a member of the group that produced the national rehabilitation pathways in cancer and has published a cookery book on diet and cancer prevention. Clare has recently published a text book entitled Nutrition and Cancer. Clare also has a research role at the Royal Marsden, encouraging and support Allied Health Professionals to undertake research in the area of rehabilitation and cancer. The Department of Nutrition and Dietetics at The Royal Marsden is actively involved in research including studies on nutrition screening, dietary interventions during radiotherapy and the nutritional status and symptoms of patients with upper gastrointestinal cancer.

Lucy Eldridge MSc RD Dietetic Team Leader Nutrition & Dietetic Department The Royal Marsden NHS Foundation Trust, UK

Lucy Eldridge is the Dietetic Team leader at The Royal Marsden. Prior to joining the Marsden in 2011 she worked for almost 15 years at Barts and the London NHS Trust working within the field of Oncology and Palliative care. As part of this role she set up and developed the dietetic service at St Josephâ&#x20AC;&#x2122;s Hospice in Hackney. In 2009 she completed her MSc in Cancer Care. She has a keen interest in the role of nutrition in palliative care and is on the committee of the national Palliative Care Dietetic Group. She has written a chapter on nutrition and palliative care and another on the psychosocial influences on food choice of cancer patients. She is an occasional guest lecturer at Kings College, University of London for dietetic students regarding palliative care and has spoken at local and national conferences on a variety of topics.

www.uaecancercongress.ae

Faculty Profile Lung Cancer Session

Abdul Rahman Jazieh, MD, MPH Chairman, Oncology Department Professor, King Saud University for Health Sciences National Guards health Affairs, Riyadh, KSA

C S Pramesh, MS, FRCS Associate Professor, Thoracic Surgery Department of Surgical Oncology, Convener, Thoracic Oncology Disease Management group Tata Memorial Centre, India

Joost Nuyttens

George R. Blumenschein, Jr., MD Associate Professor of Medicine Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, USA

George R. Blumenschein, Jr. is an Associate Professor of Medicine in the Department of Thoracic/ Head and Neck Oncology at The University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Blumenschein graduated from The University of Texas Medical School of Houston and completed a fellowship at The University of Texas MD Anderson Cancer Center, where he later accepted his current post. He has received certification from the American Board of Internal Medicine and the American Board of Medical Oncology. Dr. Blumenschein has a keen clinical interest in the development of novel therapies for head and neck cancers, small cell lung cancer and non-small cell lung cancer (NSCLC). His research has a particular focus on compounds with novel mechanisms of action, including inhibitors of epidermal growth factor, vascular endothelial growth factor and histone deacetylase. In pursuing these inter30

www.uaecancercongress.ae

Faculty Profile ests, he has taken on the role of Principal Investigator for several phase II and phase III studies to assess the efficacy of targeted agents in NSCLC. He recently presented trial data at the 13th World Conference on Lung Cancer, 2009 in San Francisco, CA, and has published work in several prestigious journals, including Journal of Clinical Oncology, Clinical Lung Cancer and Cancer.

Mehdi Shahidi MD, FRCR Associate Therapy Area Head Clinical Research - Clinical Development Boehringer Ingelheim, UK

Dr Mehdi Shahidi is the Associate Therapy Area Head, Oncology at Boehringer Ingelheim and until recently held an honorary clinical appointment at the Royal Marsden Hospital in London, UK. Prior to joining Boehringer Ingelheim in 2005, Dr Shahidi held the position of Medical Expert, Oncology at Novartis Oncology in 2004-2005 and was Medical Director of Oncology at PRA International from 2002-2004. He spent five years as a Senior Research Fellow at the Institute of Cancer Research, Royal Marsden Hospital, where he undertook research projects in urological cancers and lymphoma, and was involved in Phase I-III clinical oncology trials and direct care of patients with cancer. Prior to that, Dr Shahidi worked as a consultant clinical oncologist in two University-affiliated hospitals in Tehran, Iran. Dr Shahidi received his medical training at the National University Medical School, Iran, and his specialist training in Clinical Oncology at the Jorjani Medical Centre, Iran and the Royal Marsden Hospital, UK. He obtained the British Postgraduate Medical Federation Diploma in Clinical Oncology with distinction and completed the Postgraduate Course in Pharmaceutical Medicine. Additionally, Dr Shahidi is a Fellow of the Faculty of Clinical Oncology of the Royal College of Radiologists and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, London, UK. Dr Shahidi has presented his research at numerous international oncology congresses and has been published extensively in a range of peer-reviewed journals.

Kumar Prabhash, MD, DM, ECMO, PDCR Assoc Prof, Medical Oncology Tata Memorial Hospital, India

www.uaecancercongress.ae

Faculty Profile

Nasser Al-Dhaibani, M.D., D.I.M., F.R.C.P.C, BRACHY Radiation Oncology Department Tawam Hospital, Al Ain, UAE

Maroun Khoury Consultant Hematology/Oncology American Hospital Dubai, UAE

www.uaecancercongress.ae

Faculty Profile Breast Cancer Session

Rebecca Dent Office of Clinical Sciences, Duke-NUS Graduate Medical School, Consultant, Dept of Medical Oncology, National Cancer Centre, Singapore

Jose Baselga Associate Director, MGH Cancer Center Chief, Division of Hematology/Oncology, Massachusetts General Hospital, USA

Jose Baselga is the Chief of the Division of Hematology/Oncology and Associate Director of the Massachusetts General Hospital Cancer Center in Boston where he is also Professor of Medicine at Harvard Medical School. His research interests are in clinical breast cancer and in translational and early clinical research. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and is leading the clinical development of several new agents including pertuzumab and PI3K inhibitors. His main focus in the laboratory and in the clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents and therapeutic approaches to target the PI3K pathway. He is also leading a number of neo-adjuvant trials in breast cancer and has been at the forefront of developing biomarker-based early and translational clinical trials.

Hamdy A. Azim Prof. of Clinical Oncology Cairo University, Egypt

Hamdy A Azim is Professor of Clinical Oncology at Cairo University in Egypt. He completed his MSc in clinical oncology at the Cairo University Hospital, thereafter writing a PhD thesis on the management of non-Hodgkinâ&#x20AC;&#x2122;s lymphoma in adults. Dr Azim then obtained postdoctoral training at the Medical Oncology Department of the Institut Curie in Paris, France and at the Department of Adult Lymphoma and Bone Marrow Transplants, Hopital St. Louis in Paris. Dr Azim is a member of numerous societies including the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the European Blood and Marrow Transplantation Society (EBMT), the European Society of Medical Oncology and Oncology (ESMO), the Amer34

www.uaecancercongress.ae

Faculty Profile ican Society of Therapeutic Radiology (ASTRO) and the International Association of Ambulatory Infusional Chemotherapy, Paris (ADICCA). He sits on several scientific committees and has been an invited speaker in more than 100 regional and international conferences in the Middle East, Europe, USA and Asia. He served as a speaker for the ASCO online educational programme and represented the Middle Eastern Region on the ASCO International Affairs Committee from 1997 to 2002. His main interests lie in lymphoma, breast cancer, bone metastases and translation research where he has published more than 50 papers and 100 abstracts. Dr Azim is an editor for the Journal of Clinical Lymphoma, The Lancet (Middle East edition), and the Journal of Clinical Oncology and Nuclear Medicine. He was an educational book guest editor at the annual Kasr El Aini Center of Clinical Oncology (NEMROCK) meeting, in collaboration with MD Anderson Cancer Center (MDACC) and the French National Cancer Institute (INCA) in 2006. Dr Azim serves as referee for the Annals of Oncology Journal, THE BREAST, Chemotherapy and the Journal of the Egyptian National Cancer Institute. He has been honoured with several awards including Scientist of the Year from the International Biographical Centre, Cambridge, UK (2002), the Order of Merit, Cambridge University (2002), and the Best Arab Oncologist (1997-2000) from the Lebanese Society of Medical Oncology (LSMO). Together with international leaders of government, patient advocacy leaders, cancer research organisations and corporations, Dr Azim signed the “Charter of Pars against Cancer” on behalf of the Arab World in February 2000.

Paul Ellis Professor of Medical Oncology Guy›s & St Thomas› NHS Trust, UK

Professor Paul Ellis studied medicine at Otago University in New Zealand before completing his fellowship in Medical Oncology and his postgraduate Doctor of Medicine research degree at the Royal Marsden Hospital in London. During this time he was awarded the inaugural ASCO Fellowship Award in 1996. He took up his present post in 1997. Between 2003 and 2005 he was Head of Medical Oncology at Guy’s & St Thomas’ and is currently Medical Director for the South East London Cancer Network. He is the author of over 70 peer reviewed scientific papers with a particular focus in the fields of breast and lung cancer. He has been on the Editorial Board of a number of oncology journals including the Journal of Clinical Oncology. His major breast cancer research interests include novel clinical research strategies in the adjuvant and neoadjuvant setting with an emphasis on the integration of novel therapies. Professor Ellis was the principal investigator and co-chair of the trial management group for the national UK Adjuvant Chemotherapy (TACT) Trial. He was also co-chair of the UK Department of Health Advisory Committee for the development of national treatment guidelines for the use of Adjuvant Trastuzumab.

www.uaecancercongress.ae

Faculty Profile

Sudeep Gupta Professor of Medical Oncology Tata Memorial Hospital, India

Clifford Hudis, M.D Chief, Breast Cancer Medicine Service & Attending Physician Memorial Sloan-Kettering Cancer Centre, USA

Clifford A Hudis, MD is chief of the breast cancer medicine service and attending physician at Memorial Sloan-Kettering Cancer Centre (MSKCC) in New York City where he is also a professor of medicine at the Weill Medical College of Cornell University. He is co-leader of the Breast Disease Management Team at MSKCC, co-chair of the Breast Committee of the Cancer and Leukemia Group (CALGB), Treasurer of the American Society of Clinical Oncology (ASCO), chair of the Scientific Advisory Committee of the Breast Cancer Research Foundation, and an Associate Editor of the Journal of Clinical Oncology. Dr Hudis received his BA from Lehigh University and his MD from the Medical College of Pennsylvania in 1983 following the completion of a six-year combined BA and MD program. From 1983 through 1987 he trained in internal medicine at the Medical College of Pennsylvania and served as chief medical resident. His hematology/oncology training was completed at MSKCC in 1991 and since then he has been a member of the Breast Cancer Medicine Service at Memorial Hospital where he has conducted a large number of clinical trials. His research interests include drug development with a particular focus on the integration of newer agents into the treatment plan for patients with early stage disease. His current research focuses on the exploration and clinical translation of several signal transduction pathways including HER2 and COX2.

Omalkhair Abulkhair Section Head & Consultant, Division of Adult Medical Oncology, Department of Oncology, King Abdulaziz Medical City, National Guard Health Affairs, KSA Alfa Scan Radiology Center, Egypt

Naglaa Abdel Razek, MD Assistant Prof. of Radiology Cairo University, Egypt

www.uaecancercongress.ae

Faculty Profile

Omar Zakaria Assistant Professor of Surgery Surgical Oncology National Cancer institute, Cairo University, Egypt

Ana Maria Gonzalez Angulo, MD Assoiciate Professor ept. of Breast Medical Oncology, Dept. of Systems Biology, The University of Texas M.D Anderson Cancer Center, USA Dr. Gonzalez-Angulo, attended medical school at the Universidad del Cauca in Colombia and moved to the U.S. to continue her training. She completed a residency in Internal Medicine at the Mount Sinai Medical Center in Miami, and a Fellowship in Medical Oncology at the Ochsner Clinic Foundation in New Orleans. She then went to the University of Texas MD Anderson Cancer Center to specialize in Breast Cancer as she was selected as the Susan G. Komen Breast Cancer Fellow. She stayed at MD Anderson faculty and works exclusively with Breast Cancer patients and in Breast Cancer research. She is interested in aggressive types of breast cancer including triple receptor-negative disease. Her research focuses on mechanisms of resistance to standard breast cancer therapies, and on the development of markers to predict response to treatments using functional proteomics. She is funded by the NCI, ASCO, Komen for the Cure, AACR (SU2C) and the Commonwealth Foundation for Cancer research. She is the Chair of the Endocrine Resistance Working Group and a member of the Correlative Sciences Working Group for the Translational Breast Cancer Research Consortium, and a member of the Breast Cancer Committee of SWOG and of the BIG-NABG Triple Negative Working Group. She serves as a member of the steering committee of The United States â&#x20AC;&#x201C; Middle East Partnership for Breast Cancer Awareness and Research and the Partnership for Breast Cancer Awareness and Research of the Americas.

www.uaecancercongress.ae

Faculty Profile

Hesham El Ghazaly Professor of Clinical Oncology Ain Shams University, Egypt

Professor Hesham Elghazaly is the chief of oncology departments in General Organization of Teaching Hospitals and Institutes (GOTHI). He is assistant professor of clinical oncology, Ain Shams University. He is also the founder and president of BGICS - Breast –Gynecological International Cancer Society - which is a society aiming at promoting optimal standards of care for patients with breast & gynecological cancers. It represents a committee of the international & national members including Medical Oncologists, Surgical Oncologists, Gynecologists, Radiotherapists, Radiologists, and Pathologists exclusively dedicated to foster international multidisciplinary collaboration to highlight the updates on evidence-based practice to reach a guideline for the management of breast and gynecological cancers by the end of 2013, also aiming to establish a specialized BGICS Journal, hoping to see its 1st volume soon. The BGICC “Breast –Gynecological International Cancer Conference, www.bgicc.eg.net, is one of the main activities of the society. It is the only conference specialized in the breast & gynecological cancers in Africa & the Middle-East. Its ultimate goal is to ameliorate the prognosis and improve the quality of life of patients affected by this disease through undertaking and supporting international initiatives, sharing their experience & implementing trials and to reach a consensus regarding the management of the breast & gynecological cancer & aiming for Women Welfare. Prof. Elghazaly is also an active member of many international and national societies like American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) among others. He also achieved European certification in medical oncology. He is part of different committees concerning different types of cancer as he shares in establishing the ESMO guidelines of colorectal cancer in Lugano 2010. He is also a member of International GIT and Liver society and Egyptian Forum of Liver disease (EFLD). Prof. Elghazaly is the chairman and owner of Alfa Cure Oncology Center, which is a private center highly equipped to achieve the maximum care for patients with cancer. In the way of improvement the patient need and satisfaction, the center invites high caliber international experts for patient consultation from inside and outside the center. There is also a newly added pain clinic and nutritional clinic which help patients during treatment for achievement of best quality of life.

Edith A. Perez, M. D. Deputy Director, Mayo Clinic Cancer Center Serene M. and Frances C. Durling Professor of Medicine, USA

Edith A. Perez, M.D., is the Deputy Director of Mayo Clinic Cancer Center in Florida, Vice Chair of the Alliance for Clinical Trials in Oncology, Director of the Breast Program, and the Serene M. 38

www.uaecancercongress.ae

Faculty Profile and Frances C. Durling Professor of Medicine at Mayo Medical School. She is a cancer specialist and an internationally known translational researcher at Mayo Clinic. Her roles extend nationally, including chairing the Breast Committee for the North Central Cancer Treatment Group, as well as other positions within the American Association for Cancer Research, the American Society of Clinical Oncology and the National Cancer Institute. Dr. Perez has developed, and is involved in, a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. She also has developed studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer. Dr. Perez has authored more than 550 research articles in journals, books, and abstracts. Dr. Perez is invited frequently to lecture at national and international meetings. She serves on the editorial boards of multiple academic journals. Dr. Perez is a recipient of the following awards: Breast Cancer Research Foundation Research Grant Award (1998-2011); Horizon Achievement Award in Cancer Research (2002); North Florida Hispanic of the Year Award (2003); Mayo Clinic Outstanding Faculty Award (2002 & 2004); Mayo Clinic Distinguished Educator Award (2003); named Serene M. and Frances C. Durling Professorship of Medicine (2006); Honorary Doctorate of Letters, University of North Florida (2006); Mayo Clinic Distinguished Investigator (2007); Florida State Biomedical Research Advisory Council (BRAC) (2009-2012); membership to Alpha Omega Alpha Honor Medical Society (2009), Mayo Clinic Outstanding Course Director (2009), and the EVE Award for Lifetime Achievement (2011).

David Miles Consultant Clinical Oncologist Mount Vernon Hospital, UK

Professor David Miles is a Consultant in Medical Oncology at Mount Vernon Hospital in Northwood, Middlesex, where he specialises in the care of patients with breast cancer. He underwent his specialist training at King’s College London, University College London and Guy’s Hospital, and was awarded an Imperial Cancer Research Fund Fellowship at Guy’s Breast Unit. After completing his MD, he was appointed Senior Lecturer and Consultant at Guy’s in 1995, and he moved to his current post in 2004. His research interests include the development and investigation of novel treatments for breast cancer and he is Principal Investigator for various national and international trials, including the AvaDo (Avastin plus docetaxel) study. He has participated as Chair and speaker in many key oncology mettings, and his publications are seen in a range of high-impact journals.

www.uaecancercongress.ae

Faculty Profile

Aly Abdel Razek, M.D., FACRO Executive Director Gulf International Cancer Center Chief of Radiation Oncology, UAE

Dr. Aly Abdel Razek is the Executive Director of The Gulf International Cancer Center and the Chief of Radiation Oncology. He graduated from Cairo University and completed his Radiation Therapy Residency at Washington University School of Medicine, St. Louis, Missouri where he joined the staff of Washington University. He contributed to four Radiation Oncology Textbooks and published many papers in the field. His area of interest is radiation therapy for prostate cancer where he combined external radiation with interstitial low dose and high dose brachytherapy. He established The Gulf International Cancer Center in Abu Dhabi in 2007 and was the first to utilize PET/CT scanning in radiation therapy treatment planning in the UAE.

Muhammad Ali Chaudhry, MD Medical Director, Tawam Molecular Imaging Center Clinical Assistant Professor of Radiology Johns Hopkins University School of Medicine, UAE

Bhawna Sirohi Head, Medical and Haemato Oncology Artemis Health Institute, India

Dr. Bhawna Sirohi joined Artemis Health Institute in July 2010 as Head of Medical and Haemato-Oncology. Prior to joining Artemis, she was Director of Medical Oncology at Max healthcare which she joined in Oct 2009. Dr. Sirohi has been associated with a world renowned premier institute- Royal Marsden Hospital, UK for more than a decade and previously with Tata Memorial hospital, Mumbai. She has a special interest in Breast and GI cancers & multiple myeloma. She has been an international leader in research in cancer over a period of sixteen years. She is a leader in international societies, committees and is an innovator and senior figure of the UK and European initiative for irradiation protection. She has delivered guest lectures worldwide and oral presentations at international forum. She has more than 300 publications in indexed journals and has 81 peer-reviewed clinical papers to her credit. She is on the editorial board of Indian Journal of Medical and Pediatric Oncology and Health Positive. She is the founder President of a charity NICCI (New India Cancer Charity Initiative) which will focus on complete cancer care from screening to diagnosis to treatment for patients in rural India. 40

www.uaecancercongress.ae

Faculty Profile She is on the committee of David Adams Leukaemia Fund, UK and management committee of Can Support, a charity dedicated to palliative care for cancer patients. She is patron for voice of tobacco victims (VoTV).

Nagi S. El Saghir Professor of Clinical Medicine, Director, Breast Center of Excellence, NK Basile Cancer Institute American University of Beirut Medical Center, Lebanon

Nagi S. El Saghir is Professor of Clinical Medicine at the American University of Beirut. He received his MD from the Free University of Brussels, Belgium (1978), completed his residency in Internal Medicine at the Brooklyn Hospital-Downstate, SUNY in New York (1981), and completed his fellowship in Hematology-Oncology at St. Lukeâ&#x20AC;&#x2122;s- Roosevelt Hospital Center-Columbia University in New York (1983). He is certified by the American Boards of Internal Medicine and Medical Oncology. Professor El Saghir has over 60 publications in peer-reviewed journals and is author of the book ABC of Breast Diseases from Prevention to Treatment, in Arabic and. In addition to Editorial Boards, he is Specialty Editor of The Breast and international editor of Journal of Clinical Oncology. He is Founding and Past-President of Lebanese Society of Medical Oncology and member of the Breast Health Global Initiative (BHGI), EORTC Breast Cancer Group, ESMO Developing Countries Task Force. He served as member of ASCO International Committee and ASCO Development and Education Award working group, ESMO National and Regional Representative Committees, He is recipient of Medal of Honor for Achievements from the President of Lebanon and the Cairo University Hospitals Medal of Acknowledgement for Contributions to Cancer Care in the Arab World, Lebanese Order of Physicians, and Lebanese Association of Womenâ&#x20AC;&#x2122;s rights, among others.

Vineet Gupta, MD Diplomate American Board (Int Medicine, Hematology, Med.Oncology) Group Medical Director Health Care Global Enterprises Ltd, India

www.uaecancercongress.ae

Oncology with soul

Eisai MENA Regional Office Dubai Health Care City, AlRazi Building #64, Block B, Office 1001 P.O.Box 505182 Dubai - United Arab Emirates Tel.+9714 4471295 Fax +9714 4471299

www.uaecancercongress.ae

Faculty Profile Cancer Imaging Session

Muhammad Ali Chaudhry, MD Medical Director, Tawam Molecular Imaging Center Clinical Assistant Professor of Radiology Johns Hopkins University School of Medicine, UAE

Nasser Al-Dhaibani, M.D., D.I.M., F.R.C.P.C, BRACHY Radiation Oncology Department Tawam Hospital, Al Ain, UAE

Dorria Saleh El Sayed Salem Department of Radiology Cairo University, Egypt

Seema Kembhavi Associate Professor, Department of Radiodiagnosis Tata Memorial Centre, India

Dr. Seema Kembhavi has been an Associate Professor and Consulting Radiologist at Tata Memorial Centre since 2005, after completing her training at the same centre. Her core interest lies in Breast and Paediatric Cancer Imaging. She has been a visiting fellow at St Jude Childrenâ&#x20AC;&#x2122;s Research Hospital and the Memorial Sloan Kettering Cancer Centre in USA. She is a member of Indian Radiological and Imaging Association, Radiological Society of North America and International Society of Paediatric Oncology (SIOP). She has over 20 publications in indexed journals and has contributed several presentations and papers in breast and paediatric oncology at national/international conferences.

www.uaecancercongress.ae

Faculty Profile Atif Zaheer Assistant Professor, Department of Radiology Johns Hopkins University, USA

Atif Zaheer, MD is an assistant professor in the Department of Radiology at the Johns Hopkins University Dr. Zaheer attended medical school at the Aga Khan University. This was followed by a radiology residency at the Beth Israel Medical Center/Harvard Medical School in diagnostic radiology and a fellowship in abdominal imaging and intervention at the Brigham and Womenâ&#x20AC;&#x2122;s Hospital/Harvard Medical School. As faculty at the Johns Hopkins University, Dr. Zaheer is actively involved in research and education. He is currently the principal investigator on a large CT outcomes study identifying the underlying value of CT for common, widely accepted clinical indications in emergency department and primary care settings. He is also currently working on novel MRI techniques for diagnosing portal hypertension including the use of Magnetic resonance elastography. His other research interests include pancreatic and prostate imaging. Dr. Zaheer believes in a multidisciplinary approach for evaluation of disease and is actively involved in the multidisciplinary conferences for liver, pancreatitis and prostate. As an active member of the faculty he is a keen educator to the large residency and fellowship program as well as the in the departmentâ&#x20AC;&#x2122;s latest initiative of e-learning which involves giving didactic lectures and case based conferences to residency programs within the United States and internationally to programs in South America and the Middle East. Dr. Zaheer is an active member of several societies including the Radiological Society of North America (RSNA) and Society of Abdominal Radiology. In addition, he serves as reviewer for CME activities for the American journal of Roentgenology.

Mohei Abouzied UAE

Aly Abdel Razek, M.D., FACRO Executive Director Gulf International Cancer Center Chief of Radiation Oncology, UAE

www.uaecancercongress.ae

Faculty Profile Gyne Oncology Session Nicole D. Fleming Assistant Professor Department of Gynecologic Oncology University of Texas MD Anderson Cancer Center, USA Dr. Fleming is an Assistant Professor in the Department of Gynecologic Oncology at M.D. Anderson Cancer Center. Dr. Fleming returns to the Houston area after completing her residency training in Obstetrics and Gynecology at Duke University Medical Center and fellowship in Gynecologic Oncology at University of California at Los Angeles Medical Center. As a member of the M. D. Anderson Outreach Program, Dr. Fleming provides medical and surgical care to women with gynecologic malignancies in the greater Houston area. She has privileges at St. Lukeâ&#x20AC;&#x2122;s Episcopal Hospital, the Womanâ&#x20AC;&#x2122;s Hospital of Texas, Methodist Hospital, and Lyndon B. Johnson Hospital which enable patients to be seen in a private-practice office setting with access to the amenities and specialized services of M. D. Anderson Cancer Center including clinical trials. Dr. Fleming believes in working closely with the patient and the referring doctor in order to provide quality care through a comprehensive, multidisciplinary approach. Dr. Fleming has a special interest in minimally invasive surgery, including robotic-assisted laparoscopy, for appropriate patients with cervical, endometrial, and early-stage ovarian cancers. Minimally invasive surgery has revolutionized care for patients with gynecologic malignancies while improving patientsâ&#x20AC;&#x2122; quality of life postoperatively. In addition to providing excellent patient care, Dr. Fleming continues to pursue her research interests which include surgical innovation and outcomes in gynecologic malignancies, and personalizing treatment options for patients with ovarian and endometrial cancer. She has authored and co-authored numerous articles in peer-reviewed journals on these and other subjects. In addition, she has been invited to write book chapters on a variety of topics in gynecologic oncology. Dr. Fleming is a member of the American College of Obstetricians and Gynecologists, the American Society of Clinical Oncology, Society of Gynecologic Oncologists, and American Association of Gynecologic Laparoscopists. In addition, she serves as reviewer for several journals including Gynecologic Oncology and Annals of Surgical Oncology.

Sana Al-Sukhun Diplomat American Board of Internal Medicine/ Medical Oncology & Hematology Assistant Professor of Medicine Faculty of Medicine, University of Jordan, Jordan Dr Sana Al-Sukhun is a Consultant in Medical Oncology and Hematology in private practice. She served as Director of Breast and Gynecology Service at King Hussein Cancer Centre. She is Assistant Professor of Medicine at the Department of Hematology/ Oncology in the Faculty of Medicine at the University of Jordan. Dr Al-Sukhun is board certified from the American Board of Medical Oncology, American Board of Hematology and the American Board of Internal Medicine. She also has a Master of Science (Major in Cancer Biology). She is past president of the American Medical Graduate Society in Jordan; and an active member of various societies including the 46

www.uaecancercongress.ae

Faculty Profile Jordanian Medical Association, and the American Society of Clinical Oncology. Dr. Al-Sukhun is interested in breast & ovarian cancer, bone metastases, and translational research particularly development of targeted therapies. She authored and co-authored several scientific manuscripts in peer reviewed journals. Dr Al-Sukhun sits on several scientific committees and has been invited speaker to many national and regional conferences. She helped establish the National Breast Cancer Screening Guidelines Program in Jordan, chaired the first conference on Breast Cancer in Jordan in 2004, in addition to several local and regional conferences.

Shona Nag Jehangir Hospital, India

Luis M.Chiva, MD,PhD MD Anderson Cancer Center, Spain Head of Department of Gynecology Oncology Adjunct Professor of University of Texas, USA

Francesco Raspagliesi Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Antonio González Martin Chief of Medical Oncology Dept Centro Oncológico MD Anderson International, Spain

Antonio González graduated in medicine at University of Navarra in Pamplona (Spain), and subsequently trained in medical oncology at University Hospital Ramón y Cajal in Madrid (Spain) from 1994 to 1997. During part of 1997 he attended as an observer to The Mount Sinai School of Medicine in New York. He joined as staff member of the Medical Oncology Service at University Hospital Ramón y Cajal in 1998. From January 2009 he gained the position of Head of Medical Oncology Department at Centro Oncologico MD Anderson International Spain in Madrid, an affiliate institution of MD Anderson Cancer Centre in Houston. He specialises in the treatment of gynaecological and breast cancer and is the secretariat of the GEICO Group (Spanish group for investigation in ovarian cancer). He is also one of the GEICO representatives on the Gynecologic Cancer InterGroup, an international organisation for trials and treatment of gynaecological cancers. He is also a member of the board of the Spanish Society of Medical Oncology (SEOM).He has several publications to his name in the field of gynecological cancer, is Senior Editor of the journal Clinical and Translational Oncology, and Co-editor of the Spanish journal Revista de Ginecología Oncológica.

www.uaecancercongress.ae

Faculty Profile

Sudeep Gupta Professor of Medical Oncology Tata Memorial Hospital, India

Luis Schiappacasse Senior Staff in Radiation Oncology Academic Department of Radiotherapy Centre Oscar Lambret, France

Dr Luis Schiappacasse is a board certified Radiation Oncologist in four countries and was trained in France. He is a senior staff of the Academic Department of Radiotherapy, Centre Oscar Lambret, Lille, France. Regional referent (Nord - Pas-de-Calais region, France) for Radiation Oncology. He is a specialist in high-tech Radiotherapy (Tomotherapy, CyberKnife, more than 10 years experience in IMRT). He has a strong scientific and academic background, with studies in Methodology and ICH-GCP; lecturer / scientific programs in twelve countries. He was the scientific coordinator, 1st International Master in Advanced Technological Applications in Radiation Oncology, Spain.

www.uaecancercongress.ae

Faculty Profile Head and Neck Session

Ravinder Deo India

Chirag Shah Director, Dept. of Hematology, Oncology and Stem Cell Transplant, Apollo Hospitals International Ltd., India

Somasundaram Subramanian, MD, Surgical Oncologist; Director, Eurasian Federation of Oncology & EAFO Educational & Research Center, Russia

Pankaj Chaturvedi Associate Professor Surgical Oncology, Head & Neck Services Tata Memorial Hospital, Mumbai, India

Sangita Bhandary Vice Chancellor Patan Academy of Health Sciences, Nepal

www.uaecancercongress.ae

Faculty Profile

Balรกzs B. Lรถrincz M.D. ENT Consultant Head and Neck Surgeon Hamburg-Eppendorf University Medical Centre, Germany

Dr Balazs B Lorincz works as the lead consultant oncologic and reconstructive head and neck surgeon at the Department of ENT, Head & Neck Surgery and Oncology of the University Medical Centre Hamburg-Eppendorf, Hubertus Wald Comprehensive Cancer Centre, Germany. His special focus of interest includes transoral and transaxillary robotic surgery, microvascular free flap reconstruction of head and neck defects as well as thyroid and parathyroid surgery. He became the first and is still the only TORS-proctor for Intuitive Surgical in Germany, as well as performed the first robotic thyroidectomy in this country. He has recently established an international head and neck fellowship academic training programme at the University of Hamburg, having just welcomed his first overseas fellow from McGill University, Montreal, Canada, for the following 18 months, to share his experience in head and neck oncology and reconstruction. Dr Lorincz was appointed in his current position after having completed a 2-year head and neck clinical fellowship in Australia, having spent his first year in the Princess Alexandra Hospital in Brisbane, followed by a second year in the Sydney Head and Neck Cancer Institute at the Royal Prince Alfred Hospital in Sydney. During his time in Australia, he gained invaluable experience in the multidisciplinary management of head and neck cancer patients, including microvascular free flap reconstruction, thyroid surgery and robotic surgery. Prior to his fellowship, he completed his residency and registrar training at the University of Bergen, Norway and in the National Institute of Oncology, Budapest, Hungary, where he originally comes from. Dr Lorincz now lives in the hanseatic city of Hamburg with his physician wife and their two sons, currently expecting their third child to be born in 2013.

Dhairyasheel Savant Consultant Surgical Oncologist Reconstructive & Microvascular Surgeon, India

Arif Jamshed Consultant Clinical Oncologist Shaukat Khanum Memorial Cancer Hospital and Research Centre India

www.uaecancercongress.ae

Faculty Profile

Raghav Dwivedi UK

Ajit Venniyoor, MD, ECMO, DNB, DM Senior Consultant (Med Oncology) The Royal Hospital, Oman

Dr Ajit Venniyoor is currently serving as Senior Consultant in Medical Oncology at the National Oncology Centre in Royal Hospital in Muscat, Sultanate of Oman. He did his primary medical training in Armed Forces Medical College, Pune, India and served with distinction in the Indian Armed Forces from 1982 in various parts of India and abroad including Sri Lanka and Bhutan. He did his MD in Internal Medicine from the same college and DNB from National Board of Examination, New Delhi. He then did DM in Medical Oncology from Cancer Institute in Chennai, India and also trained in Stem Cell Transplant from Northwestern Memorial Hospital in Chicago. After serving in various oncology centres in Mumbai, Delhi and Lucknow, he took voluntary retirement from the service in 2010 and joined a private hospital in Mumbai, the 1500-bedded SevenHills Hospital, where he helped to set up the Oncology department. He then joined the present post in Jun 2011. Dr Venniyoor has many articles to his credit in various Indian and international journals. His areas of interest included head and neck cancer and GI malignancies. He is a member of many societies including ESMO and ICON. He has also been a teacher in the several hospitals that he worked in India.

Tanguy Y. Seiwert, MD Assistant Professor of Medicine The University of Chicago Medicine, Chicago, USA

Dr. Tanguy Seiwertis a specialist in head and neck cancer as well as lung cancer. Dr. Seiwert has a special interest in developing improved treatment strategies for these diseases. He looks for new ways to combine traditional treatments, such as chemotherapy and radiotherapy, with the latest targeted agents, in order to improve treatment results and decrease side effects. Dr. Seiwertâ&#x20AC;&#x2122;s research focuses on the biology of head and neck cancer and lung cancer. In the laboratory, he studies targeted therapies that disrupt specific pathways vital to cancer growth and metastasis. He studies which novel drugs appear most promising, which individual tumors are more likely to respond to these treatments, and how to successfully combine therapies. Dr. Seiwert uses this pre-clinical knowledge to develop new treatments for use in clinical trials, and to ultimately improve patient care.

www.uaecancercongress.ae

Faculty Profile Gouri Pantvaidya MS, DNB, MRCS Associate Professor, Head and Neck Surgery Tata Memorial Hospital, Mumbai, India

Gayle Woodson, MD, FACS Professor & Chair of Otolaryngology Southern Illinois University School of Medicine Director, SIU Voice Center, St. John’s Hospital, USA

Dr. Woodson is professor and chair of otolaryngology at the Southern Illinois University School of Medicine and director of the SIU Voice Center at St. John’s Hospital. She completed two years of training in general surgery at Johns Hopkins Hospital, a residency in otolaryngology at Baylor College of Medicine, and a fellowship in laryngology in London. Dr. Woodson is a past president of the American Laryngological Society as well as the Society of University Otolaryngologists. She has served as examination chair on the American Board of Otolaryngology (ABO) and as chair of the Residency Review Committee for Otolaryngology. Other prior service includes the Board of Directors of the ABO, the Board of Directors of the American Academy of Otolaryngology, and the Council of the American Society for Head and Neck Surgery. She has received numerous awards, including Presidential Citations from the American Laryngological Society and the American Academy of Otolaryngology, and the Chevalier Jackson Award. She has been elected to the Johns Hopkins Society of Scholars. Dr. Woodson has authored or coauthored more than 100 scientific articles and book chapters and textbooks and has lectured extensively around the world. Her research in laryngeal physiology addresses treatment of the paralyzed larynx.

Cesare Piazza, MD Assistant Professor Department of Otorhinolaryngology – Head and Neck Surgery, University of Brescia, Italy

Cesare Piazza, MD is Assistant Professor of the Department of Otorhinolaryngology – Head and Neck Surgery at the University of Brescia, Italy. He received his MD degree at the University of Pavia and he completed his residency programme in Otolaryngology in Brescia. His clinical and research activities are focused on head and neck oncology, with special emphasis to laryngeal, tracheal, oral and reconstructive surgery. Dr. Piazza is an active member of the European Laryngological Society since 2000 and is part of its Scientific Council since September 2010. He authored or co-authored 52 papers in peer-reviewed journals as well as 55 book chapters. He delivered 265 proffered papers and invited lectures in national and international Congresses and Courses.

www.uaecancercongress.ae

Faculty Profile

Shishir Shetty, M.Ch (Surgical Oncology).M.S Professor and Head Department of Surgical Oncology, Dr D.Y Patil Medical College, Hospital & Research Center, India Dr Shishir Shetty is a post graduate and super speciality guide and teacher. He was the first qualified surgical oncologist to be trained at Tata Memorial Hospital, India. He has special interest in trachea, lung, pancreas and liver surgeries. He trained in Emmory University, Atlanta, U.S.A and is currently the president of Cancure Foundation.

Vedant Kabra Senior Consultant Surgical Oncologist Max Cancer Centre, India

Dr Vedant Kabra graduated from Institute of Medical Sciences, Banaras Hindu University, India in 1995 with the “University Gold Medal”. He completed his masters in General Surgery from the same Institute in 1998 and was judged the “Best Resident of the Institute”. His thesis paper was awarded the “Best Research Paper” at the Annual conference of Association of Surgeons of India. Dr Kabra completed three year Senior Residency program at Tata Memorial Hospital, Mumbai and also did fellowships in Head & Neck Surgery and Breast surgery at the same hospital. Thereafter, he worked as Assistant Surgeon at Asian Institute of Oncology, Mumbai. His presentations were awarded at various oncology conferences. Dr Kabra obtained membership of Royal Colege of Surgeons of Edinburgh in 2002. He also worked as a fellow and associate at National Cancer Centre of Singapore from Jan 2005 to Oct 2006. He has been a faculty at national and international conferences, has contributed 3 book chapters and several articles in peer-reviewed journals and is a member of several reputed Societies and Associations. Dr Kabra joined Max Healthcare in 2007 and is currently working as Senior Consultant Surgical Oncologist at Max Cancer Centre, Max healthcare, New Delhi.

Hussain Abdulrahman, Msc (Cairo), FRCS Consultant & Head of ENT Department Dubai Hospital, UAE

www.uaecancercongress.ae

Faculty Profile

Cyrus Kerawala Head & Neck Unit Royal Marsden Hospital, UK

Cyrus Kerawala graduated with an honours degree in medicine from St Georgeâ&#x20AC;&#x2122;s Hospital, London and an honours degree in dentistry from the Royal London Hospital. During training he was awarded 17 undergraduate prizes. After experience in general surgery and neurosurgery he spent five years of specialist head and neck training in the North East of England. Cyrus passed the Intercollegiate Examination in Maxillofacial Surgery in September 1998 and has been on the Specialist Register of the General Medical Council since August 1999. He worked as a Consultant at the Royal Surrey County Hospital in Guildford and North Hampshire Hospital in Basingstoke for eight years before joining the Head and Neck Unit at the Royal Marsden Hospital in 2008. Cyrus is the current Honorary Secretary of the British Association of Oral and Maxillofacial Surgeons and Associate Editor of the British Journal of Oral and Maxillofacial Surgery. He is also Chairman of the Education and Training Committee of the International Association of Oral Oncology and Chairman of the Norman Rowe International Education Foundation. Cyrus is author of a book on Maxillofacial Surgery and has written numerous chapters in other books. He has also authored over 60 peer-reviewed publications. He devotes a significant amount of time to teaching, professional training and continuing medical education. He has presented over 100 papers at international and national meetings and has been invited to lecture throughout Europe, America, the Middle East, Asia and Australia. In 2011 Cyrus carried out the first trans-oral robotic resection of a tumour in the UK. In the same year he was featured in The Times newspaper as one of Britainâ&#x20AC;&#x2122;s 50 top surgeons

Shaesta Mehta India

Shashikant Juvekar, MD Professor and Consultant Radiologist Department of Radiodiagnosis Tata Memorial Centre, India Dr. Shashikant Juvekar MD is a Professor and Consultant Radiologist in the Department of Radiodiagnosis at Tata Memorial Centre. Dr Juvekar studied at Seth G S Medical College and King Edward VII Memorial Hospital in Mumbai, India; University of Bombay. This was followed by radiology training at King Edward VII Memorial Hospital Mumbai, India; University of Bombay. 54

www.uaecancercongress.ae

Faculty Profile His areas of interest are Head and Neck Radiology, Neuroradiology and Musculoskeletal Radiology. He is an ardent believer of multidisciplinary approach and is active member of Hospitalâ&#x20AC;&#x2122;s Disease Management Groups in Head and Neck, Neuro-oncology and Musculoskeletal Oncology. He has been a visiting fellow at Withington Hospital, Manchester, UK:, MD Anderson Cancer Centre, Houston, Texas, USA and Stanford Medical Center, Stanford university, California, USA. He is a member of Indian Radiological and Imaging Association. He has several publications in indexed journals and has contributed presentations and papers at national and international conferences. He is Member of the Tata Memorial Centreâ&#x20AC;&#x2122;s Institutional Review Board and Radiation safety Committee. As faculty at Tata Memorial Centre he is actively involved in research and education.

Vishal Rao India

Chetna Bakshi India

Sankar Srinivasan, MD, MBBS Sr Consultant, Medical Oncologist Apollo Specialty Hospital, India

Sandeep Goyle India

www.uaecancercongress.ae

Faculty Profile

Ashish Bakshi India

Shailesh Bondarde India

Nirmal Raut India

Suraj Pawar Chairman & Managing Director Kolhapur Cancer Centre, India

Kumar Alok Pathak Professor and Director of Surgical Fellowship University of Manitoba, Canada

www.uaecancercongress.ae

Faculty Profile

Namrata Satyapal Senior Consultant, Radiation Oncology National Oncology Center, Royal Hospital, Oman

Dr Namrata Satyapal is currently serving as Senior Consultant in Radiation Oncology at the National Oncology Centre in Royal Hospital in Muscat, Sultanate of Oman. She did her primary medical training from King Edward Memorial Hospital and Seth GS Medical College, Mumbai, India with distinction in Pharmacology. She went on to do Diploma in Medical Radiation Therapy from the esteemed Tata Memorial Hospital and Center, Mumbai and passed with Distinction and stood First in Mumbai University in 1997 followed by MD Radiotherapy from Tata Memorial Hospital and DNB (Radiotherapy) in May 1998 from National Board of Examination, New Delhi. She subsequently joined as Lecturer and Head of Department, Cama and Albless Hospital which is part of JJ Group of Hospital, Mumbai till 2004.She moved to National Oncology Center, Oman in 2004 when the new State of Art Radiation Oncology Department was started in December 2004. She also has UICC Fellowship to her credit in Stereotactic Radiotherapy from Royal Marsden NHS Trust Hospital, London in 2009. Dr Satyapal has articles to her credit in various Indian and international journals and has several presentations in National and International Conferences. Her areas of interest include Neuro-Oncology, stereotactic radiotherapy, IMRT in various cancer sites and GI malignancies. She is life member of AROI and UICC.

Mahesh Goel India

K. Thomas Robbins, MD, FRCSC, FACS Division of Otolaryngology-Head and Neck Surgery Southern Illinois University School of Medicine, USA

K. Thomas Robbins is a native of Corner Brook, Newfoundland, Canada. He received his undergraduate education at Memorial University of Newfoundland, and his graduate degree from Dalhousie University School of Medicine. He pursued residency training in otolaryngology at Dalhousie University and the University of Toronto. He subsequently served as a head and neck fellow at the Institute of Laryngology and Otology, University of London, under the mentorship of the late Sir Donald Harrison, and as a visiting fellow at MD Anderson Cancer Center. His first faculty appointment was at the University of Texas, Houston, and subsequently at MD Anderson Cancer Center. This was followed by a faculty

www.uaecancercongress.ae

Faculty Profile position with the University of California, San Diego, and then in the Department of Otolaryngology Head and Neck Surgery, University of Tennessee, Memphis, where he was Chair. K. Thomas Robbins has also served as Chair in the Department of Otolaryngology-Head and Neck Surgery, University of Florida, and the Division of Otolaryngology-Head and Neck Surgery, Southern Illinois University. In 2004, he was appointed the Director, SimmonsCooper Cancer Institute at Southern Illinois University and appointed the Executive Director, Simmons Cancer Institute at Southern Illinois University in 2012. He is married to Dr. Gayle Woodson, a fellow academic otolaryngologist. Their family includes Philip and daughter-in-law Jessie, Nicholas, Gregory, Sarah, and grandchildren Evan and Kate.

Nagao Toru Division Chief and Director Oral and Maxillofacial Surgery and Stomatology Okazaki City Hospital, Japan

Dr.Toru Nagao is a Division Chief and Director of Department of Oral and Maxillofacial Surgery and Stomatology, Okazaki City Hospital, Japan, and has been involved in surgical oncology of oral, head and neck cancer and precancer. He is an Associate Professor in the Department of Oral and Maxillofacial Surgery, Aichi-Gakuin University School of Dentistry, Japan. He obtained a PhD at Aichi-Gakuin School of Dentistry in 1990. Since 1999 he has been Senior Research Fellow in the Oral Medicine&Experimental Oral Pathology, WHO Collaborating Centre for Oral Cancer/Precancer, Guy’s, King’s&St. Thomas’ Dental Institute, London, UK. Dr.Nagao has publications on the subjects of oral cancer screening, serum antioxidant micronutrients levels in oral precancerous lesions and other epidemiological studies on oral diseases. He obtained a DMSc at Fujita Health University School of Medicine, Japan in 2007 and a visiting professor of Department of Preventive Medicine, Fujita Health University School of Medicine.Dr.Nagao has been contributed to the development of oral cancer control as well as dental education in developing countries. From 2001 to 2003, he worked in Sri Lanka as a Chief Advisor to Dental Education Project in the Faculty of Dental Sciences, University of Peradeniya, which was implemented by Japanese Overseas Development Assistance through Japan International Cooperation Agency(JICA). During his assignment he has been active in lectures throughout the world on topics of oral cancer prevention. He organized an oral cancer seminar for regional countries such as India, Bangladesh, Nepal, Myanmar, Cambodia, Philippines, Indonesia and Madagascar, where oral cancer was public health problem.

Kumar Prabhash, MD, DM, ECMO, PDCR Assoc Prof, Medical Oncology Tata Memorial Hospital, India

www.uaecancercongress.ae

Faculty Profile

Vedang Murthy, MD, DNB, DipEPP Associate Professor and Consultant Radiation Oncologist, Tata Memorial Hospital, India

Vedang Murthy, MD, DNB, DipEPP, is an Associate Professor and Consultant Radiation Oncologist at Tata Memorial Hospital, Mumbai, a premier oncology centre in Asia. Dr Murthy’s current area of expertise is in Head and Neck Oncology and Urological Cancer. He has special interest in high precision radiotherapy procedures such as Image Guided Radiotherapy and Adaptive Radiotherapy. Dr. Murthy did his training in the field of Radiation Oncology from Tata Memorial Hospital in 2002 before proceeding to the UK. He worked at The Royal Marsden NHS Foundation Hospital, London for a period of 4 years in the Academic Radiotherapy Unit. He also undertook a Diploma in Epidemiology and Biostatistics from the London School of Health and Tropical Medicine. He has over 35 publications in various peer reviewed international journals.

Devendra Chaukar Associate Professor & Surgeon ‘F’ Head &Neck Oncology, Tata Memorial Hospital, India

Dr Chaukar was awarded the Hargobind fellowship for training in advanced laser surgery at Kiel in 2006. He attended a course on randomized clinical trial held at Oxford by INDOX, from 6 – 10 September 2010.

Vikram Sanghvi Consultant Surgical Oncologist Surgical Oncology, Bombay Hospital, India

Sarmistha Gupta Specialist Radiologist Radiology Department NMC Speciality Hospital, Dubai, UAE Dr. Sarmistha Gupta has done her post graduation, MD, DNB, DMRD Radiodiagnosis from Tata Memorial Hospital, Mumbai, India in 1999, which is a premiere cancer institute of South East Asia. After completing residency, she worked in many esteemed institutes of India as Consultant Radiologist. Her areas of special interest are Head and Neck imaging, women’s imaging and Abdominal

www.uaecancercongress.ae

Faculty Profile imaging through CT, MRI and sonography. She has been actively involved in research work involving radiology in breast diseases , early radiological detection of cervical metastasis in head and neck cancer, coeliac ganglion block in intractable pain of pancreatic cancer to name a few. She has participated in many National and International Conferences as speaker and has many publications to her credit in indexed journals. At present she is working as a Specialist Radiologist in NMC Specialty Hospital, Dubai.

Adilbay Dauren MD, PhD Chief of Head and Neck Oncology Department Astana Oncology Center, Kazakhstan

Dr Adilbay Dauren MD, PhD is chief of Head and Neck oncology department at Astana oncology center, Kazakhstan. Dr Adilbay did his medical schooling and post graduation in Almaty state medical university named after S. D. Asfendiarov. He was adjudged the best Intern and the best post graduate during his tenure in Kazakh Institute of oncology, Almaty, Kazakhstan. Later, he decided to work in field of head and neck surgical oncology and received his residency training at N.N. Blokhin cancer center in Moscow, Russia on the basis of governmental grant. He was awarded IDEA grant of ASCO to visit MD Anderson cancer center and ASCO annual meeting in 2009. Passed short trainings in head and neck departments of European Institute of oncology in Milan and in Amrita Institute of medical sciences, India. He is member of ASCO, ESSO and Eurasian head and neck oncology society. He has authored 1 book chapter and 12 papers in peer reviewed journals. He is a scientific coordinator of Eurasian head and neck oncology society and very actively involved in the organizing of related meetings and in composing of scientific program. From September 2012 he become chief of new opened head and neck oncology department in Astana oncology center, Kazakhstan. Department will cover nearly 3 million population of northern part of Kazakhstan. Dr. Adilbay also received his masterâ&#x20AC;&#x2122;s degree in public health and actively involved as a consultant and organizer in public campaigns held by Together against cancer NGO.

Mandar Deshpande India

Dr. Mandar Deshpande is a consultant Surgical Oncologist (Head and Neck) at Kokilaben Dhirubhai Ambani Hospital, Mumbai, India. Dr. Deshpande did his medical graduation from LTM medical college and Sion Hospital, Mumbai 1989 -93. He did his MS in General Surgery and DNB from prestigious Tata Memorial Hospital, Mumbai in 1998. After that he did rotating surgical oncology residency in various departments of Tata Memorial Hospital for period of 3 years from 1998 to 2000. He was a senior research fellow in Dept of Surgical oncology from 2000 to 2002. In 2002, he was appointed as a consultant and Assistant Professor in Department of Head and Neck Oncology, Tata Memorial 60

www.uaecancercongress.ae

Faculty Profile Hospital Mumbai. He was promoted to the position of Associate Professor in 2008. In 2009, shifted to Kokilaben Dhirubhai Ambani Hospital in western suburbs of Mumbai. Here he is working as a consultant Head and Neck Surgical Oncologist for last 3 years. Dr. Deshpande has 37 peer reviewed publications and more than 50 presentations to his credit. He was the principle investigator of â&#x20AC;&#x2DC;Oral Cancer Adjuvant Therapy OCAT trialâ&#x20AC;&#x2122; at Tata Memorial Hospital. He is been co-investigator on more than 15 trials and studies. His fields of interest are Post laryngectomy voice rehabilitation and Robotics in Head and Neck surgery.

Aly Abdel Razek, M.D., FACRO Executive Director Gulf International Cancer Center Chief of Radiation Oncology, UAE

Andrei Karpenko Head of Department, Head and Neck Surgery LeninGrad Regional Oncologic Dispenscery, Russia

Nilesh Lok India

S.V.S. Deo Additional Professor, Surgical Oncology AIIMS, New Delhi, India

www.uaecancercongress.ae

Faculty Profile

Tarini Sahoo India

Seema Kembhavi Associate Professor, Department of Radiodiagnosis Tata Memorial Centre, India Dr. Seema Kembhavi has been an Associate Professor and Consulting Radiologist at Tata Memorial Centre since 2005, after completing her training at the same centre. Her core interest lies in Breast and Paediatric Cancer Imaging. She has been a visiting fellow at St Jude Childrenâ&#x20AC;&#x2122;s Research Hospital and the Memorial Sloan Kettering Cancer Centre in USA. She is a member of Indian Radiological and Imaging Association, Radiological Society of North America and International Society of Paediatric Oncology (SIOP). She has over 20 publications in indexed journals and has contributed several presentations and papers in breast and paediatric oncology at national/international conferences.

Deepak Sarin, MBBS, MS (ENT), DNBE (ENT), FHNS (USA) Associate Director Department of Head & Neck Surgery Medanta, The Medicity, India Dr Sarin completed his medical school (MBBS) from the All India Institute of Medical Sciences. He subsequently did his Residency in Otolaryngology (ENT) and Head & Neck Surgery also from the All India Institute of Medical Sciences. He graduated with the Kamani Charity Trust Prize (Gold Medal) as well as the Mukut Sahariya Award. In 2003, he was accepted as a Clinical Fellow in the Head & Neck and Skull Base Surgery Program at the Sylvester Comprehensive Cancer Center at the University of Miami in Florida, USA. During his tenure there for 2 years he received advanced training in his field and performed close to 600 state of the art operations. He was also awarded the Chandler Society Award in 2005 for his research in the spread of cancer. He moved back to India in 2005 and set up the Department of Head & Neck Surgery at Sir Ganga Ram Hospital. In 2007 he moved to Artemis Health Institute where he worked till 2011. He is currently at Medanta, The Medicity in Gurgaon where he heads the department of Head and Neck Oncology Surgery. He maintains a strong interest in the treatment of mouth and thyroid cancer.

www.uaecancercongress.ae

Faculty Profile

Salim Chaib-Rassou Snr Consultant & A/Chair Tawam Hospital, UAE

Dr. Salim Chaib Rassou graduated as Medical doctor in 1988 from Constantine Algeria. He obtained his specialist diploma with outstanding rate on 1992, from Bourgogne University under supervision of Pr J.C Horiot. He has received post graduate diplomas in breast diseases and breast imaging. He worked in different hospitals in France and held different positions as senior staff. He took part in different phase III trials as investigator, mainly in head and neck cancer, breast cancer and lung cancer. He passed with success the French national competitive for (praticien Hospitalier) and held this position for 3 years. He keeps in touch with all the new developments in Radiation Therapy by attending several courses and congresses (has accumulated an average of more than 200 CME hours per year). His main interests are H & N, Gynaecology, Breast and Brain tumours. He has co-authored 3 majorâ&#x20AC;&#x2122;s publications and 5 abstracts. After introducing 3 D CRT in all cancer localisation, he is in charge of developing new other techniques, IMRT, IGRT with Tomotherapy machine and Varian LA.

Jamil Uddin Hyder, MBBS, DLO, FRCS Otolaryngologist and Head & Neck Surgeon Al Nahda Hospital, Ministry of Health, Oman

Dr Hyder is a fellow of Royal College of Physicians and surgeon of Glasgow. He acquired his Otolaryngology training from United Kingdom. Later he served at The Aga Khan University Hospital Karachi as full time faculty. His sub specialty interest is Head & Neck surgery. He has vast experience of undergraduate and post graduate teaching. He participated in establishing residents training programme at Aga Khan University Hospital and currently he is Chair of the Curriculum sub committee of Otolaryngology residency program of Oman Medical Specialty Board. He organizes the yearly Head and Neck Cadaver dissection course at Al Nahda Hospital Muscat. He has many publications to his credit.

www.uaecancercongress.ae

Faculty Profile GI Surgical Oncology Workshop Jorg Kleeff, MD, FACS Professor of Surgery, Department of Surgery Technische Universität München, Germany

Jorg Kleeff, MD, FACS is Professor of Surgery and Vice-Chairman of the Department of Surgery, Technische Universität München (Munich, Germany). He started his medical education at the renowned Medical Schools of the Universities of Tübingen and Munich, Germany. Dr. Kleeff continued his scientific career as a postdoctoral research fellow at the University of California in Irvine, USA under the guidance of Prof. Murray Korc. Following these two years of research work, he started his clinical training at the Department of Visceral and Transplantation Surgery at the University of Bern, Switzerland. From 2001 to 2007 he worked at the Department of Surgery at the University of Heidelberg (Chairman: Prof. Markus W. Büchler). Since 2007 he has been working at the Department of Surgery, Technische Universität München (Chairman: Prof. Helmut Friess). Dr. Kleeff has published more than 200 peer-reviewed articles (h-index: 40) in internationally recognized medical journals as well as over 120 review articles and book chapters. According to the Essential Science Indicators, he is a top-ranking molecular scientist in the field of pancreatic cancer research. Dr. Kleeff has given lectures at a number of international meetings and is member of different societies like the Society of Surgeons of the Alimentary Tract (SSAT), the American Gastroenterology Association (AGA), European Digestive Surgery (EDS), among others. His clinical work focuses on oncological surgery of the hepato-pancreato-biliary system as well as of the upper and lower gastrointestinal tract. The molecular biology research focuses on pancreatic cancer, specifically on the interaction of cancer cells with the tumor microenvironment (stellate cells, inflammatory cells), therapy resistance,and mechanisms of perineural invasion and metastasis. He is heading a multinational research lab (www.pankreasforschung.de) and is involved in collaborative projects with the German Cancer Research Centr (DKFZ) and several national and international Universities.

Michael L. Kendrick Chair, Division of GI and General Surgery Associate Professor of Surgery Mayo Clinic College of Medicine, USA Dr Michael Kendrick is an Associate Professor of Surgery in the Division of Gastroenterologic and General Surgery at the Mayo Clinic in Rochester Minnesota. He received his MD, degree from George Washington University in Washington, D.C. Doctor Kendrick did his general surgery residency at the Mayo Clinic College of Medicine in Rochester, Minnesota. After residency, he completed additional training as a Mayo Foundation Scholar in hepatobiliary surgery at the Mayo Clinic and Minimally invasive surgery at Mount Sinai in New York, He is currently Chair of the Division of Gastroenterologic and General Surgery, and Director of the Minimally Invasive Surgery Fellowship Program in the Division of Gastroenterologic and General Surgery at the Mayo Clinic Rochester. His interest include laparoscopic and open management of pancreatic and hepatobiliary diseases. 64

www.uaecancercongress.ae

Faculty Profile

Shailesh V. Shrikhande Associate Professor of Surgery, GI & HPB Surgical Oncology Tata Memorial Centre, India

Dr. Shailesh V. Shrikhande is Professor of Surgery and Head of GI and HPB Surgical service at the Tata Memorial Center in Mumbai, India. He has received specialist training in Pancreatic Research and Pancreatic Surgery at the University of Bern, Switzerland and the University of Heidelberg, Germany. He was later the first Asian to be awarded the Kenneth Warren Fellowship of the International Hepato-Pancreato-Biliary Association (IHPBA) in 2005. He has been invited for over 150 lectures and orations all over India and other parts of the world. Apart from published over 100 clinical and basic science research papers, Dr. Shrikhande has also given live operative demonstrations on pancreatic, gastric and colorectal cancer. In addition, he has contributed over 40 book chapters and is the Chief Editor of the book “Surgery of Pancreatic tumors” (2007) and “Pancreatic Cancer: Current Understanding” (2011). To promote awareness on pancreatic tumors in this part of the world, he founded the website www.pancreaticcancerindia.com both for professionals and lay people. He is the Associate Editor of Indian Journal of Colorectal Diseases and also Langenbecks Archives of Surgery. He is also on editorial and review boards of many international journals dealing with GI and HPB surgery.

George Karimundackal, MRCSEd, MCh Associate Professor, Thoracic Services Tata Memorial Centre, India

Bhawna Sirohi Head, Medical and Haemato Oncology Artemis Health Institute, India

Dr. Bhawna Sirohi joined Artemis Health Institute in July 2010 as Head of Medical and Haemato ncology. Prior to joining Artemis, she was Director of Medical Oncology at Max healthcare which she joined in Oct 2009. Dr. Sirohi has been associated with a world renowned premier institute - Royal Marsden Hospital, UK for more than a decade and previously with Tata Memorial hospital, Mumbai. She has a special interest in Breast and GI cancers & multiple myeloma. She has been an international leader in research in cancer over a period of sixteen years. She is a leader in international societies, committees and is an innovator and senior figure of the UK and European initiative for irradiation protection. She has delivered guest lectures worldwide and oral

www.uaecancercongress.ae

Faculty Profile presentations at international forum. She has more than 300 publications in indexed journals and has 81 peer-reviewed clinical papers to her credit. She is on the editorial board of Indian Journal of Medical and Pediatric Oncology and Health Positive. She is the founder President of a charity NICCI (New India Cancer Charity Initiative) which will focus on complete cancer care from screening to diagnosis to treatment for patients in rural India. She is on the committee of David Adams Leukaemia Fund, UK and management committee of CanSupport, a charity dedicated to palliative care for cancer patients. She is patron for voice of tobacco victims (VoTV).

www.uaecancercongress.ae

Faculty Profile GI Session René Adam Centre Hépato-Biliaire Paul Brousse Hospital, France

René Adam is President of the Medical Board of the Paul Brousse Hospital, Villejuif, France and Head of the Oncological Surgery Unit of the Hepato Biliary Center. Since 1994, he has held the position of Professor of Surgery at the Faculty of Medicine Kremlin Bicêtre at Paris South University, Paris. Professor Adam’s main fields of activity and research are surgery of the liver, biliary tract and pancreas, and hepatic transplantation. He is particularly involved in the treatment of hepatocellular carcinoma and of liver metastases. Professor Adam chairs the European Liver Transplant Registry and LiverMetsurvey, the international Registry of Colorectal liver metastases. He is on the Editorial Board of The Oncologist and member of several international societies, including the American Society of Clinical Oncology (ASCO), the European Society of Surgical Oncology (ESSO), the European Society of Organ Transplantation (ESOT), the European Surgical Association (ESA) and the International Hepato-Pancreatic and Biliary Association (IHPBA). He is member of the board of the French Association of Surgery and, of the French Association of Hepato-Biliary Surgery and Liver Transplantation. He has delivered more than 600 lectures on his research interestsaround the world, and has more than 200 publications in peer-reviewed journals.

Shailesh V. Shrikhande Associate Professor of Surgery GI & HPB Surgical Oncology Tata Memorial Centre, India

www.uaecancercongress.ae

Faculty Profile

Bhawna Sirohi Head, Medical and Haemato Oncology Artemis Health Institute, India

Dr. Bhawna Sirohi joined Artemis Health Institute in July 2010 as Head of Medical and Haemato Oncology. Prior to joining Artemis, she was Director of Medical Oncology at Max healthcare which she joined in Oct 2009. Dr. Sirohi has been associated with a world renowned premier institute Royal Marsden Hospital, UK for more than a decade and previously with Tata Memorial hospital, Mumbai. She has a special interest in Breast and GI cancers & multiple myeloma. She has been an international leader in research in cancer over a period of sixteen years. She is a leader in international societies, committees and is an innovator and senior figure of the UK and European initiative for irradiation protection. She has delivered guest lectures worldwide and oral presentations at international forum. She has more than 300 publications in indexed journals and has 81 peer-reviewed clinical papers to her credit. She is on the editorial board of Indian Journal of Medical and Pediatric Oncology and Health Positive. She is the founder President of a charity NICCI (New India Cancer Charity Initiative) which will focus on complete cancer care from screening to diagnosis to treatment for patients in rural India. She is on the committee of David Adams Leukaemia Fund, UK and management committee of CanSupport, a charity dedicated to palliative care for cancer patients. She is patron for voice of tobacco victims (VoTV).

Eric Van Cutsem, MD, PhD Digestive Oncology, Leuven Cancer Institute University Hospital Gasthuisberg, Belgium

Professor Eric Van Cutsem is Professor at the University of Leuven, Belgium. He is responsible for the Department of Digestive Oncology at the University Hospital Gasthuisberg in Leuven. Professor van Cutsem obtained the degree of medical doctor in 1983 at the University of Leuven, specialised in internal medicine and obtained his PhD degree in 1994. During his training he spent several months in England, Switzerland, the USA and the Netherlands involved in clinical and research projects. His main research interest is the treatment of gastrointestinal tumours and he has published more than 150 peer-reviewed articles (120 in pubmed) and more than 250 other texts or chapters in books. His work has appeared in respected publications such as the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, British Journal of Cancer and Gastroenterology. He also co-ordinates several European and worldwide trials investigating new drugs for gastrointestinal cancer and serves on many steering committee and advisory boards. Professor Van Cutsem is a member of several scientific organisations, including the American Society of

www.uaecancercongress.ae

Faculty Profile Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the American Association of Cancer Research (AACR), the European NeuroEndocrine Tumor Network (ENET) and many national organisations. He was member of the programme committee of ASCO 2003-2004 and is member of the ASCO Cancer Education Committee 2005-2008 and is chairman of the ECCO 2005 colon cancer committee. He is president of the Belgian FAPA (Familial Adenomatous Polyposis Association) and served as secretary of the European Organization for Research and Treatment of Cancer - Gastrointestinal Cancer Group (EORTC-GI group) from January 2000 till February 2003. He became chairman of the EORTC GI group in March 2003. He is member of the general assembly of PETACC (Pan European Trials on Adjuvant Colon Cancer). Professor Van Cutsem is the co-editor of GI News, the newsletter of the EORTC-GI-group and is a member of the editorial board of Journal of Clinical Oncology, Annals of Oncology, European Journal Cancer, Japanese Journal Clinical Oncology, Clinical Colorectal Cancer, European Journal of Cancer Prevention, Journal of Chemotherapy, Expert Opinion of Pharmacotherapy as well as several others. He was organiser of the PICC (Perspectives In Colorectal Cancer) meetings in Barcelona and is chairman of the scientific committee of the World Congress in Gastrointestinal Cancer in Barcelona in June 2004.

Syed Mansoor Hasnain MBBS, FRCS (Glasg), FFR RCSI, CCST Radiation Oncologist, Tawam Hospital, Al Ain, UAE

Syed Mansor Hasnain is a Radiation Oncologist at Tawam Hospital, Al-Ain, UAE. He also maintains administrative responsibility of acting chair for radiation oncology. He has a double fellowship FRCS (Glasg) in surgery and FFR RCSI (Fellow of Faculty of Radiology, Royal College of Surgeons in Ireland) in radiation oncology. He has received specialist registrar training from Saint Lukeâ&#x20AC;&#x2122;s Hospital, Dublin. He has completed CCST and entered as a specialist register in Medical Council, Ireland. His special interest is radiotherapy treatment of gastrointestinal tumours, Urology, Breast and Lymphoma. Tawam hospital is the only Public hospital in UAE with radiotherapy facility. He is a clinical leader for GI tumoursin radiotherapy department and patients of rectal cancers visit him for radiotherapy treatment from all 7 states in UAE. He makes sure the patients are staged properly, and their cases discussed in tumour board before any active treatment is started. He also shares evidence based practice for rectal cancers with his surgical colleagues.

Hassan Jaffar Medical Consultant Tawam Hospital (affiliated with Johns Hopkins) Al Ain, UAE

Dr. Jaafar received his M. B. Ch. B (MD) in 1992, the internal medicine board in 1997, and he passed the Arab board exam in internal medicine. He completed a 3 years of fellowship in hematology oncology and is certified as a medical hematologist oncologist from American university hospi70

www.uaecancercongress.ae

Faculty Profile tal of Beirut in the year 2000.He is the author and co-author of 17 peer reviewed papers and abstracts and is involved in more than 6 ongoing phase II and phase III trials (regional like GORG gulf oncology research group and international). He is a lecturer in Al-Ain university faculty of medicine and a member of numerous medical societies (UAE Oncology and radiation therapy association, Lebanese hematology and oncology association, ESMO European society of medical oncology and ASCO American society of clinical oncology)

Marc Peters

Axel Grothey Professor of Oncology & Consultant Mayo Clinic Cancer Center, USA

Axel Grothey gained his medical degree from the Ruhr-University in Bochum, Germany. After completing a fellowship in hematology/oncology in Germany and a post-doctoral fellowship in Biochemistry and Molecular Biology at MD Anderson Cancer Center in Houston, Texas, he became senior attending oncologist at the University of Halle, Germany. He is now a Professor of Oncology and Consultant in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He is the Vice Chair of the North Central Cancer Treatment Group (NCCTG) and the co-chair of the NCCTG GI committee. Dr. Grotheyâ&#x20AC;&#x2122;s major areas of clinical interest are GI malignancies, in particular, colorectal cancer, unknown primaries, and neuroendocrine tumors.

Ranga Rao, VSM, MD, DM Director, B L Kapur Cancer Centre Senior Consultant & HOD, Dept of Medical Oncology BLK Superspeciality Hospital, India

www.uaecancercongress.ae

ONCOLOGY FROM ONCOLOGY FROMINGELHEIM ONCOLOGY FROM BOEHRINGER BOEHRINGERINGELHEIM INGELHEIM BOEHRINGER ONCOLOGY FRO BOEHRINGER IN VALUE THROUGH INNOVATION VALUE THROUGH INNOVATION VALUE THROUGH INNOVATION

VALUE THROUG

ONCOLOGY FROM BOEHRINGER INGELHEIM VALUE THROUGH INNOVATION

oncology from boehringer ingelheim oncology boehringer ingelheim oncology fromfrom boehringer ingelheim

W. JOB No. 7711477 W. Job No. 7411110 ZE: 340mm x 210mm ESCR:

12/07/2010 12/07/2010 16:23 1

Don’t forget to register and collect your «Lung Cancer Curriculum DVD» at the Boehringer Ingelheim booth Op. Co. CLIENT: BI PRODUCT: ONC

DATE 040610 CREATED BY: PJA AMENDED BY: KB PROOF NO. 01

HW. JOB No. 7711477 RW. Job No. 7411110 SIZE: 340mm x 210mm DESCR:

oncology from boehringer ingelheim

www.uaecancercongress.ae

ONC-MENA-2012-00001

7711477_Pipeline_Brochure_A4.indd 1

12/07/2010 16:23

Faculty Profile Breast Surgical Workshop

Dhairyasheel Savant Consultant Surgical Oncologist Reconstructive & Microvascular Surgeon, India

Vinay Deshmane, MS, DNB, FRCS (Glasg), MD (London), FICS Consultant, Surgical Oncology & Breast Diseases, India Dr. Vinay Deshmane trained at the Grant Medical College and Sir JJ Group of Hospitals, Mumbai. He received his Masters degree in General Surgery (1987), standing third in the University of Mumbai and was admitted as a Diplomate of the National Board (General Surgery) by the National Board of Examinations, New Delhi. Thereafter, he trained and worked in Surgical Oncology at the Tata Memorial Hospital, Mumbai, for a period of 7 1/2 years following which he undertook specialist training in Breast Cancer at the Sir Hedley Atkins Breast Unit, Guy’s Hospital, London. Here over a period of 6 years, besides honing his clinical skills he spent time in laboratory research at the Richard Dimbleby Department of Cancer Research/ Imperial Cancer Research Fund, St. Thomas’ Hospital, London. His work on DNA methylation, in relation to the menstrual cycle and timing of breast cancer surgery led to a “Doctor of Medicine” award from the University of London in 2001. During this period he was admitted as a Fellow of the Royal College of Surgeons of Glasgow. He has received a “Young Scientist” award from the Indian Society of Oncology, a “Outstanding paper” award from the International College of Surgeon and Fellowships from the International Cancer Federation (UICC, Geneva), Imperial Cancer Research Fund (ICRF, UK) and the Breast Cancer Campaign (UK). His areas of special interest include: Breast cancer, oncoplastic surgery, molecular biology of cancer and tumour profiling. He works in Mumbai and is associated with the P.D Hinduja National Hospital, The Asian Institute of Oncology and The Breach Candy Hospital. He is a managing committee member of the Indian Cancer Society and the Association of Breast Surgeons of India, and is the coordinator for the Educational Task force initiative of the Indian Cancer Society.

Sanjay Sharma, MS.FICS.FAIS.FACS Mumbai Cancer Clinic, India

Dr Sharma was in Oncology/Onco surgery at Tata Memorial Hospital (Cancer Hospital) Bombay, initially as Resident and later on as a Surgeon from 1979 to till 2003. He also par ticipated in the Nargis Dutt Memorial Fellowship for training in Cancer at The Sloan Kettering Cancer Centre, New York, U.S.A. and Specialised training in Thoracic Oncology, Critical Care from 1982 – 1983.

www.uaecancercongress.ae

Faculty Profile He has given over 1,000 guest lectures , symposiums and orations on cancer esophagus, cancer lung, cancer breast, cancer stomach, GI malignancies, pancreatic cancer ovarian and cervical Cancer. He has also appeared in over 75 Publication in National and International peer reviewed journals on varied subjects from breast cancer to esophageal cancer, Lung Cancer, tenting, laser and endo- bronchial surgery. He is a member of several eminent medical societies and maintains/ maintained academic positions at several institutions such as Bombay Hospital, Asian Institute of Oncology, Tata Memorial Hospital and Mumbai University.

Sanjay Deshmukh India

Seema Kembhavi Associate Professor, Department of Radiodiagnosis Tata Memorial Centre, India

Syed Mansoor Hasnain, MBBS, FRCS (Glasg), FFR RCSI, CCST Radiation Oncologist, Tawam Hospital, Al Ain, UAE

www.uaecancercongress.ae

Best Abstracts T Regulatory Cells in the DCIS Microenvironment Induce Myoepithelial Apoptosis: A Role in Transition of DCIS to Invasive Disease? Introduction: The microenvironment in DCIS is complex and the myoepithelial cell, which forms the major barrier between the epithelial and stromal compartments, may play a key role in disease progression. We previously have shown that myoepithelial cells in DCIS display an altered phenotype, with up-regulation of the integrin αvβ6, switching myoepithelial function from tumour suppressor to tumour promoter. Amis: This study investigates the relationship between myoepithelial phenotype and T regulatory infiltrate, and the influence this has on myoepithelial integrity. Methods: Immunohistochemistry on DCIS cases with myoepithelial cells positive or negative for αvβ6 was performed for CD4 and Foxp3 to detect regulatory T cells. Serial sections also were stained for galectin-7, a myoepithelial-restricted protein that is anti-apoptotic. myoepithelial cell line negative for β6 (β4myo) was generated from reduction mammoplasty material, and a β6 positive (β6 myo) line was generated from this by viral transduction and was shown to be functional. Since T regulatory cells produce TRAIL that can induce apoptosis, we investigated the hypothesis that αvβ6-positive myoepithelial cells may be more susceptible to TRAIL-induced apoptosis, leading to loss of the myoepithelial barrier. The cells were exposed to recombinant TRAIL for different time periods and then assayed for evidence of apoptosis by detection of cleaved PARP. The effect of loss of Galectin-7 on myoepithelial apoptosis was examined following knockdown of Galectin-7 using siRNA, compared to non-targeting control, and then treated with TRAIL. Isolated primary breast cells population (luminal epithelial and myoepithelial cells) and β4 and β6 myoepithelial cell lines were subjected to PCR and western blotting for the anti-apoptotic Galectin-7. Results: Significantly higher levels of CD4+ve and FOXP3+ve cells were detected around β6+ve DCIS ducts compared to β6-ve ducts (n=130; P=0.0001), indicating that αvβ6 expression is associated with extensive T regulatory cells infiltration. β6+ve and β6-ve myoepithelial cells were exposed to TRAIL and this demonstrated TRAIL enhanced apoptosis, measured by cleaved PARP, in β6+ve cells. Furthermore these cells showed loss of the anti-apoptotic protein Galectin 7, and knockdown of Galectin-7 in normal β6-ve myoepithelial cells rendered them more susceptible to TRAIL-induced apoptosis. In DCIS tissues, an inverse relationship between αvβ6 and Galectin-7 in myoepithelial ells was demonstrated. Conclusion: These data suggest that αvβ6 expression by DCIS myoepithelial cells is related to enhanced T reg cell infiltration, and these myoepithelial cells are more susceptible to TRAIL-induced apoptosis, in part through loss of Galectin-7. These changes may play a key role in breaking down the myoepithelial barrier in DCIS. Acknowledgements: This work was funded by Libyan Government, Ibn Sina Teaching Hospital, Althahdi University, Sirte Libya. Authors: Khairiya Ahmed, Michael Allen, Jenny Gomm, John Marshall, J Louise Jones Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London.

www.uaecancercongress.ae

Best Abstracts Targeted Agents Matched with Tumor Molecular Aberrations: Molecular Aberrations, Targeted Therapy and Outcome in A Phase I Clinic Background: Identification of activating mutations in melanoma has increased the number of novel targeted agents for this disease. Methods: We retrospectively reviewed clinical outcomes of 160 consecutive metastatic melanoma patients (pts) treated in the Dept of Investigational Cancer Therapeutics (Phase I program) at M. D. Anderson since 2008, and compared their median progression free survival (PFS) to their first and last standard systemic therapy PFS. In addition, we compared those ptsâ€™ outcomes tested for tumor molecular aberrations on a phase I trial with a matched targeted agent with those of pts who were treated without regard for their molecular profiles. Results: Of 160 pts treated on 35 different phase 1 clinical trials, 110 pts (69%) had â‰¥ 1 molecular aberration. Of those pts who had adequate tissue for molecular analysis, 63% (85/134) pts had BRAF mutation, 20% (22/109) NRAS mutation, 20% (1/5) GNAQ mutation, 11% (1/9) P53 mutation, 2.5% (1/39) PIK3CA and 1.3% (1/76) had KIT mutation. 77 (48%) pts were treated on a phase I trial with a matched targeted agent and 83 (52%) pts were treated on a non-matched phase 1 trial. The overall response rate was 39% (complete response [CR], 9%; partial response [PR], 30%) in the 77 pts treated with matched therapy and 9% (all PRs) in the 83 pts treated without matched therapy (P = 0.0018). 139 (87%) pts received at least one systemic therapy before referral to phase I, median PFS was longer on phase 1 therapy than on last line standard therapy prior to referral to phase 1 (4.2 vs. 2.8 months, P = 0.002). Median PFS was greater for pts on matched vs. non-matched therapy (5.3 vs. 3.7 months, log rank P = 0.004). Also, median PFS was longer on phase 1 matched trial than on first standard treatment (5.3 vs. 3.9 months, log rank P = 0.045).PFS did not differ between first standard and non-matched phase 1 study. Univariate analyses with the log rank test revealed that matched therapy (P = 0.004) was positively associated with longer PFS on phase 1clinical trials. Conclusions: Matching melanoma pts with targeted drugs based on specific molecular aberrations in the phase I setting can be associated with superior outcomes compared to prior standard systemic therapies. Author: Haby Henary, Md Anderson Cancer Center, Houston, Texas, USA.

Dendritic Cell Therapy in Patients with Refractory Solid Tumours

Purpose: Dendritic Cell Therapy (DCT) initiates immune response against malignant tumors. A multi-centric study ongoing in India has the objective to evaluate toxicity and efficacy in refractory solid tumours. Method: DCT is prepared by using of Peripheral Blood Mononuclear Cells (PBMCs), cultured with cytokines (IL4 and GMCSF) and exposed to antigen retrieved from patientsâ€™ own tumour tissue. Mature DCs (Dendritic Cells) harvested on Day 8 are checked for surface markers (CD 80 + (PE)CD 86+ (APC) and CD 83+( FITC) positive) and adequate counts ( > 1 X million DCs) per dose. Patients with recurrent solid malignancies only on symptomatic care were recruited. 6 doses of DCT were administered over 14 weekâ€™s period. Response evaluation was done using RECIST-version 1.1 (Response Evaluation Criteria for Solid Tumours) and irRC (Immune Related Response Criteria). Per Protocol Objective Response (OR) includes Stable Disease (SD), Partial Response (PR) and Complete Response (CR). Response assessments will be done three times at Week 8 (before dose 4), Week 14 (before dose 6) and Week 26 from start of therapy. Results: Safety: 51 patients (ovary-9, colon and rectum- 7, head & neck -6, lung-5, Prostate- 5, sarcoma-4, breast-4, stomach-3, cervix-3, squamous cell carcinoma of heel-1, pancreas-1, melanoma-1, renal cell-1

www.uaecancercongress.ae

Best Abstracts and Cholangiocarcinoma-1) enrolled, received at least one dose, were evaluated for safety. 225 infusions have been completed; all were well tolerated, except for a single episode of rigors during infusion. 2 patients developed deep vein thrombosis, both with relapsed gynaecologic malignancies and gross disease in the pelvis and retro-peritoneum. The other adverse events reported were due to disease progression. The most common serious adverse events recorded were dysponea, abdominal distension and pain, were associated with the primary cancer and metastatic sites and considered unlikely to be related to the therapy. Response: 36 patientsâ€™ Week 8 response: OR 23/36 (64%) by irRC 10/36 (28%) by (RECIST). 1 is PR for 2 consecutive visits. 21/36 patients returned for Week 14 assessment: OR is 10/21 (48%) by irRC and 7/21(33%) by RECIST. 13 did not undergo Week 14 assessment (4 withdrawn and 9 died). The overall OR at Week 14, is 10/34 (29%) by irRC and 7/34 (21%) by RECIST. 2 patients have yet to be assessed. Only 1 patient has completed Week 26 and continues with OR. There are trends that suggest patients with chronic disease (disease period of 45 months), fewer metastatic sites and less prior chemotherapy failures; breast, ovary and prostate cancers have responded well. 16 out of 51 patients are on trial. 8 are alive after withdrawal and 1 completed all visits. 26 patients died due to disease progression. Survival data is still maturing. Conclusion: DC therapy is safe and extremely well tolerated. Response data is encouraging. More survival data is needed to conclude survival benefit. Ethics Approval and Funding: Study was initiated after obtaining Ethics Committee clearance from all the participating trial sites. The study is funded by APAC Biotech Pvt. Ltd. 69, JCM, DLF Phase II, Gurgaon 122002, Harayana, India. Authors: Poonamalle Parthasarathy Bapsy, Apollo Hospitals Bangalore, India. Sharan Bandan, Kumar Chaitanya, Anjum Mahmood, APAC Biotech Pvt. Ltd, Rangarajan Bharath, Narayana Hrudayalaya Hospitals, Jain Minish, Ruby Hall Clinic, India, AVS Suresh, Bibi General Hospital, India, S Subramanian, V S Hospital, India, Rajappa Senthil, Indo-American Cancer Centre, India, Srivastava Mala, Nextvel Consulting LLP, India

Risk Factors for Breast Cancer

Background: Many risk factors for breast cancer have been identified, including alcohol consumption, body mass index (BMI), oral contraceptive pills (OCP) and hormonal replacement therapy (HRT). Some evidence suggests that these variables as well as other lifestyle factors, such as tobacco smoking, affect prognosis. The purpose of this study was to investigate the effect of these factors on survival after diagnosis of breast cancer. Methods: We used data from women with invasive breast cancer who had taken part in the Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) (1). The association between alcohol intake, smoking, BMI, OCP and HRT, and breast cancer specific survival (BCSS) was investigated using Cox regression. We modelled alcohol consumption, pack year of smoking and BMI as both continuous variables and as ordinal variables (alcohol consumption Results: Data on 13,525 cases were available for analysis with 6.7 years median follow-up. In univariate analyses, improved prognosis was seen with increasing current alcohol consumption, with a 2% (95% CI, 1-3%) reduction in the risk of death per unit of alcohol consumed per week. The HR per unit increase in ordinal category was 0.87 (95% CI: 0.81-0.96). The association with better prognosis was slightly stronger in patients with ER negative tumours (HR: 0.74; 95% CI: 0.60-0.90) compared with patients with ER positive tumour (HR 0.91; 95% CI 0.82-1.01) (P=0.067). Adjusting for tumour stage and histopathological grade gave similar estimates. Women who received HRT had better BCSS (HR 0.77; 95% CI 0.69-0.87). This effect was limited to ER positive disease. BMI was associated with a 1.9% (95% CI 0.9-2.9%) increase in mortality per unit increase. The associations of OCP use and BMI were attenuated and were not statistically significant 78

www.uaecancercongress.ae

Best Abstracts when adjusted for stage and grade. Smoking and history of OCP use were not associated with BCSS. Conclusion: The prognosis of breast cancer is poorer in women who are overweight, but better in women with moderate alcohol consumption. These findings are consistent with previously published data (2, 3). HRT use was associated with a better prognosis in women with ER positive tumours. If confirmed, these findings have implications for counselling women being treated for breast cancer. References: (1) Barnett GC, Shah M, Redman K, et al. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008;2620:3310-6. Authors: Alaa M.G. Ali1, 2, Mitul Shah3, Douglas F. Easton1, 3, Paul D. Pharoah1, 3 Author affiliations: 1 Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK 2- Department of Biostatistics and Cancer Epidemiology, South Egypt Cancer Institute, University of Assiut, Egypt 3 - Department of Oncology, University of Cambridge, Cambridge, UK.

Insulin Upregulates Pyruvate Kinase M2 Expression but Downregulates its Activity to Promote Cancer Metabolism: Understanding Hyperinsulinism and Elevated Cancer Incidence Purpose and Relevance: Evidences in recent years have suggested a critical role of insulin in cancer cell growth and survival. High levels of endogenous insulin among type-2 diabetics and non-diabetics have also been associated with increased cancer risk in epidemiological studies with highest risk for liver and pancreatic cancer. Significantly, insulin receptor has been reported to provide resistance to IGF-1R targeted therapies emphasizing the importance of targeting insulin signaling. The role of insulin, however, in regulation of cancer cell metabolism is still obscure. The present study investigates the role of insulin in cancer metabolism. Since PKM2 has recently gained enormous attention for its decisive role in regulating metabolism of cancer cells and; cancer metabolism is now perceived at the heart of anti-cancer strategies, we explored the potential effect of insulin on PKM2 status with associated implications on metabolic behavior of cancer cells. Methods: Insulin-sensitive hepatocellular carcinoma cell line (HepG2) was used. Real time PCR and Western blotting was performed to analyze PKM2, HIF1Î± mRNA and protein respectively. Spectrophotometer was used for enzyme kinetics and studying metabolic behavior of cancer cells. Density gradient centrifugation was used for subunit dissociation studies. Fluorescence spectrophotometry was done for ROS analysis. PKM2 knock down studies were performed using shRNA cloned in lentiviral vector pGIPZ. Appropriate statistical analysis performed to calculate significance of data. Results: We show that insulin upregulated PKM2 expression but reduced its activity, in HepG2 cells. Interestingly, insulin induced reduction in PKM2 activity was PI3K/mTOR independent. Drop in PKM2 activity was attributed to subunit dissociation leading to formation of low activity PKM2 oligomers, as assessed by density gradient centrifugation. Notably, phosphorylation of PKM2 at tyrosine 105 remained unaffected on insulin treatment, which suggested an involvement of other insulin-induced factor(s) in PKM2 activity regulation. Interestingly, we identified role of insulin-induced ROS in PKM2 activity reduction. Insulin promoted aerobic glycolysis through PKM2 upregulation which was confirmed by PKM2 knockdown experiment. The PKM2 activity reduction was associated with characteristic pooling of glycolytic intermediates and increased accumulation of NADPH; suggesting diversion of glucose flux towards macromolecular synthesis, necessary for cancer cell growth. The study identified new PKM2-mediated effects of insulin, thus, advancing the understanding of insulinâ€™s role in cancer. Conclusions: Our study highlights previously unknown PKM2-mediated effects of insulin in promotion of cancer metabolism, which may explain increased risk of cancer with hyperinsulinemia that has been linked with increased susceptibility to liver cancer both in type 2 diabetic and non-diabetic patients. Our results also suggest that increasing PKM2 activity may have therapeutic implications in inhibiting cancer metabolism.

www.uaecancercongress.ae

Best Abstracts We acknowledge UGC, Govt of India for providing research funds. Authors: Mohd Askandar Iqbal, National Centre of Applied Human Genetics, School of Life Sciences, Jawaharlal Nehru University, India. Rameshwar NK Bamezai

Involvement of HPV Genotypes and TP53 G72C Polymorphism in Cervical Cancer in Saudi Arabia

Purpose: Cervical cancer is the second most common cancer among women worldwide; however, it ranks number 15 in Saudi Arabian women forming only 2.2% of newly diagnosed cases. Muslim women were suggested to have lower incidence of human papillomavirus (HPV) infection, a main risk factor, raising the question of important environmental, cultural and genetic differences among countries. Since only a subset of HPV infected patients eventually develop cervical cancer; genetic predisposition may play a role in the process of carcinogenesis. In this project we have investigated the relationship between HPV infection, genotype and the presence of single nucleotide polymorphisms (SNPs) in TP53 G72C tumor suppressor gene with the occurrence of cervical cancer. Methods: Genetic polymorphisms of 170 cervical cancer patients (cases) were compared with 306 normal volunteers with no history of cancer (controls). DNA was extracted from paraffin embedded cervical tumor tissues. HPV detection and genotyping were carried out using the HPV Linear Array Test (Roche Diagnostics), which enables the detection of 37 most common high- and low-risk HPV genotypes. In controls, DNA was extracted from peripheral blood. TP53 G72C SNP was assessed by direct sequencing. Results: Patients age ranged between 28 and 106 (median=46) years old. By histology 79% had squamous cell carcinoma while 21% had adenocarcinoma. HPV was detected (positive) in 141 patients (83%). Fifteen different HPV genotypes were detected, 12 high-risk (16, 18, 31, 33, 39, 45, 51, 52, 56, 59, 73 and 82) and 3 low-risk (6, 64 and 70) with 15 patients having double infections, mainly HPV-16 and 18. The most common single genotypes were 16 (65%), 31 (7%), 45 (6%), 18 (5%) and 73 (2%). With double infections, HPV-16 and 18 were the two most common genotypes present in 66% of cervical cancers, and forms 79% of all HPV-positive patients. Interestingly, the genotype and allelic distributions of TP53 G72C SNP were comparable between cases (G/ G=0.21, G/C=0.53, C/C=0.26) and controls (G/G=0.22, G/C=0.58, C/C=0.20). Consequently, there were no significant differences (P>0.05) suggesting that this SNP is not involved in cancer predisposition in this cohort. Conclusions: The rate of HPV infection in our cervical cancer patients (83%) is at the lower range of what has been estimated worldwide (85-99%). HPV 16 and 18 were present in 66% of our patients. Therefore, current HPV vaccines are expected to protect more than two-third of cervical cancer women in Saudi Arabia. Genetic predisposition data did not reveal any association between HPV infection and TP53 G72C SNP. Although the incidence of cervical cancer in Saudi Arabia is low, this study provides important information for national screening and HPV-vaccination guidelines that are expected to protect predisposed women from invasive cervical cancers. The project was approved by the IRB and supported by KACST grants LGP-12-4, ARP-27-12, and KFSHRC grants (RAC#2060-027, 2060-029, 2100-010). Authors: Alsbeih G1; Al-Harbi N1; Al-Qahtani S1, Venturina LA1, Al-Buhairi M1, El-Sebaie M2, Mahmood R2, Al-Dehaim M2, Khalil E2, Ahmed R2, Albadawi I3, Balaraj K2. 1Biomedical Physics, 2Radiation Oncology, 3Obstetrics & Gynecology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

www.uaecancercongress.ae

Best Abstracts Comparative Evaluation of HP DNA Versus Colposcopy as Secondary Cervical Cancer Screening Tests to Triage Screen Positive Women on Primary Screening by VIA Purpose: Evidence base for VIA (Visual Inspection with 5% Acetic Acid) as a low cost screening method has been sufficiently established with the limitation of low specificity. The present study therefore evaluates the performance of secondary testing by HPV DNA and Colposcopy in a single-visit screening approach to increase program effectiveness in limited health care resources settings. Method: In a Cross sectional cervical cancer screening trial, 3629 women (30-65 years) were screened by primary screening test VIA. VIA test positive women were subsequently tested for the presence of oncogenic HPV types by Hybrid Capture II (HC-II) with colposcopy. The reference investigation histopathology was performed for all primary screen positive women and for 10% of the primary screen negative women. Results: Out of the total 3629 women screened 16 refused biopsy. Data for 3613 evaluable women showed 352 (9.7%) women positive on primary screening by VIA. Amongst the 352 VIA positive women, 39 ( 11%) were found positive on HPV DNA test and 43(12.2%) had Colposcopy impression for CIN2 & above lesion. VIA as a primary screening test had sensitivity of 93% (95% CI: 0.76 - 0.99) and specificity of 91% (95% CI: 0.90 - 0.92) respectively to detect CIN 2 & above lesions. HPV DNA and Colposcopy as secondary tests to triage VIA positive women had a sensitivity of 61% (95% CI: 0.41 - 0.78), 43% (95% CI: 0.24 - 0.63) and specificity of 99% (95% CI: 0.99 - 1.00), 99% (95% CI: 0.99 - .99) respectively for detecting CIN 2 &above lesions. Conclusion: VIA as sole primary screening test performed under standardized conditions with quality checks showed highly acceptable test charachteristics. An affordable HPV DNA as a triage test would auger well with resource constrained settings. Keywords: Cervical cancer screening, HPV DNA test, Colposcopy. Ethical Approval: The project was approved by the Institutional Scientific and Ethics committee under Project No 264 of Tata Memorial Hospital. Funding acknowledgements: The project was funded by the American Cancer Society under grants received from the Stephanie Lane Study. Authors: Sharmila Pimple1, Surendra Shastri2. Preventive Oncology Services, Tata Memorial Hospital, Mumbai, India.

Targeting Src Family Kinases as Novel Therapies for Breast Cancer Brain Metastases

Among 1.3 million women diagnosed with breast cancer every year, about 10-16% develop brain metastases. Despite the better control of primary tumor and improved overall survival of breast cancer patients, the incident of developing life-threatening brain metastasis is increasing (>30%). At present, no effective drug treatment exists for patients with refractory breast cancer metastatic to the brain. Therefore, novel and effective therapeutic approaches are urgently needed for this population. Unfortunately, developing effective therapeutics for brain metastasis is largely hampered by a lack of in-depth understanding of the basic mechanisms of brain metastasis. Here, we reveal a critical role of Src activation in promoting breast cancer brain metastasis. Using protein array analyses, we found that Src is hyper-activated in in vivo selected brain-seeking human breast cancer cell lines compared to their corresponding parental cells and in patientsâ&#x20AC;&#x2122; brain metastasis tumors compared to primary breast cancers. Mechanistically, Src activation in tumor cells promoted

www.uaecancercongress.ae

Best Abstracts tumor cell extravasation into the brain parenchyma via permeabilization of the blood-brain barrier. We then tested Src-targeting combinatorial regimen for preventing and treating brain metastases. We found that a clinically applicable Src-targeting agent (Saracatinib) coupled with an EGFR/HER2-dual targeting agent (lapatinib) exhibited a significant pre-clinical efficacy in preventing the outgrowth in the brain of disseminated breast cancer cells through induction of cell cycle arrest. More importantly, the combinatorial treatment also significantly inhibited established experimental brain metastases and doubled survival of 60% of mice having brain metastases (p=0.004, log-rank survival test). Our results highlight a highly promising, clinically applicable, Src-targeting regimen for breast cancer patients suffering brain metastasis. Our findings could be readily translated to clinical trials as new therapies for breast cancer patients with brain metastasis. Siyuan Zhang1,2, Wen-Chien Huang1,2, Chenyu Zhang1, Frank J. Lowery1, Lin Zhang1, Patricia S. Steeg3, Dihua Yu1 1Departments of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA, 3Womenâ&#x20AC;&#x2122;s Cancers Section, National Cancer Institute, USA, 2These authors contributed equally to this work. Author: Dihua Yu, The University of Texas MD Anderson Cancer Centre, USA

Hypo Fractionated Radiation Therapy versus Conventional Radiation in the Adjuvant Setting of Breast Cancer; Is There any Difference in Toxicity? The aim of the current study is to compare between two different fractionation schedules of adjuvant breast irradiation regarding the difference in their toxicity profiles: the conventional radiation versus hypo fractionation. This is a prospective randomized study done in breast cancer patients referred for adjuvant radiation therapy after surgery. Patients were randomized between 2 arms: Either conventional radiation schedule (CFR) : 5000 cGy/25 fractions/ 5 weeks given as 200 cGy per fraction as daily treatments for 5 consecutive days and week end days as rest.[Total 5 weeks]. Or Hypofrationated radiation schedule (HFR): 4005 cGy/ 15 fractions / 3 weeks given as 267 cGy per fraction as daily treatments for 5 consecutive days and week end days as rest. [Total 3 weeks]. Acute radiation reactions were observed during the radiation therapy sessions and graded as per RTOG scale and documented. A comparison was done between the incidence of these acute radiation reactions and different variables as radiation therapy schedule, type of surgery, and number of surgically resected lymph nodes. 78 patients were included in the study. 57.7% had breast conservative surgery; and 42.3% had modified radial mastectomy. HFR received by 53.8%; while CFR received by 46.2%. Grade 0-II radiation dermatitis seen in 86%, and Grade III, IV reactions were seen in 14%. On univariate analysis ; there was a statistically significant difference between the two radiation therapy arms regarding radiation reactions with a higher incidence (22%) in CFR as compared to only 7% in HFR group (p value: 0.004).while the other variables (type of surgery , number of surgically resected nodes) were not statistically significant. On multivariate analysis: the only variable with a statistical significance regarding the incidence of radiation reaction was radiation therapy schedule with a higher incidence in CFR (P value: 0.03). There is a statistically significant less incidence of acute radiation reactions associated with HFR as compared to CFR in the adjuvant radiation of breast cancer. Author: Ehab Esmat Fawzy, Faculty of Medicine, Cairo University, Egypt

www.uaecancercongress.ae

Best Abstracts Prevalence of Functional Impairment among Gynecological Cancer Survivors in the United States, Influence of Obesity, and Comorbidity Burden Introduction: Most gynecological cancer survivors (GCS) are obese, a critical risk factor for increasing the risk for morbidity and mortality among this population. Obesity, along with other factors, may influence functional impairment, increasing the risk of poor quality of life. The present study sought to 1) estimate the prevalence of functional impairment among obese GCS and 2) examine the relationship of obesity and comorbidity with functional impairment. Methods: We used data from the 2009, Behavioral Risk Factor Surveillance System survey. The analysis was conducted using SAS survey procedure to account for complex sampling design. Survey sampling weights were applied to gain representation of GCS living in the United States. The study included 1,984,624 GCS aged 20-100 who were â‰¥1 year post-diagnosis. Functional impairment was defined as a limitation in carrying out activity due to physical, mental or emotional problem, or requiring the assistance of special equipment. Multivariable logistic regression was used to examine the association between obesity and comorbidity burden, and functional impairment after adjusting for sociodemographic, medical, and lifestyle characteristics. Results: The prevalence of functional impairment was 48% among obese GCS compared to 28% in normal weight GCS. The unadjusted odds for functional impairment were 1.64 (95% CI, 1.28-2.10) in overweight and 2.32 (95% CI, 1.80-3.00) in obese GCS compared to normal weight GCS. The adjusted odds ratios for functional impairment were 1.32 (95% CI, 1.01-1.72) in the overweight GCS group and 1.82 (95% CI, 1.37-2.41) in obese GCS. Likewise, the comorbidity burden was significantly associated with functional impairment among GCS. An increasing number of comorbidities was associated with a higher risk of functional impairment. GCS with >2 comorbidities had 4 times increased odds (OR, 4.21; 95% CI, 2.89-6.15), and GCS with 1-2 comorbidities had twice as much risk (OR, 1.86; 95% CI, 1.35-2.56) for functional impairment compared to GCS with no comorbidities. Conclusions: The GCS population faces a significant burden of functional impairment that is influenced by higher weight status and presence of comorbid conditions. These findings highlights the need to involve primary care physicians in designing effective interventions to manage obesity and the comorbidity burden among this population to reduce functional impairment and improve their quality of life. Author: Pratibha Parelkar, MPH (1,2), Hoang Thanh Nguyen, PhD (1), and Linda S. Elting, DrPH (1) Author Affiliations: 1) Department of Biostatistics, Section of Health Services Research, The University of Texas MD Anderson Cancer Center. 2) Health Promotion and Behavioral Sciences Department, The University of Texas Health Science Center at Houston Funding Acknowledgment: The University Cancer Foundation and the Duncan Family Institute for Cancer Prevention and Risk Assessment via the Cancer Survivorship Research Seed Money Grants at the University of Texas MD Anderson Cancer Center, and from the CPRIT through the CERCIT grant (Grant No#RP101207 P04 02- L. Elting, PI) to University of Texas Medical Branch at Galveston.

www.uaecancercongress.ae

ATLAS

MEDICAL Atlas Medical was founded in 1975. Our basic guiding philosophy is to make available to the U.A.E. health care sector best of solutions by importing and distributing state-of-the-art medical equipment, medical devices and instruments, pharmaceuticals, training and education, throughout the U.A.E. Atlas Medical has a team of experienced dynamic sales, project and service personnel located in Abu Dhabi and Dubai with our offices and service centres to ensure prompt technical back-up services. All our service engineers are factory trained. COMPANIES WE REPRESENT: We represent more than 60 worldâ&#x20AC;&#x2122;s leading manufacturers including Philips Medical systems, Accuray, Cardiac science, Teleflex, Terumo, Acumed, Owandy, Medgraphics, Orthoscan, Cooper Surgical, Ondal, Schyns, Mindray, Anetic Aid, Kenex, Fiochetti, Inner space, Nidek, Agencinox, Burdick, Medical illumination, Medisun, Ferno, Yanga and many more.

OUR VISION: To improve lives with advanced technology that is easy to experience and designed around you. OUR PROJECTS: We do commercial integration for multi-modality multi-departmental turnkey projects including infrastructural development, equipment planning sourcing & financing, site planning and project management. Atlas Medical & Philips Healthcare has a partnership spanning nearly 4 decades in the U.A.E. symbolizing a strong association. Jointly we have substantial experience in healthcare imaging and hospital turnkey projects successfully executed over the last 4 years in UAE alone. A combination of world class standards with local experience ensures your project is executed smoothly. Our experienced and qualified project team is backed by government approved civil electro-mechanical sub-contractors. Prominent Govt. Customers: Presidential Affairs, Sheikh Khalifa Medical city, Ministry of Health, Health Authority of Abu Dhabi, Corniche Hospital, Mafraq Hospital, Al Ain Hospital, Tawam Hospital, Department of Health â&#x20AC;&#x201C;Dubai, GHQ Armed Forces, Ministry of Interior, ADNOC etc. Prominent Private Customers: Canadian Speciality Hospital, American Hospital, NMC Group, Prime Medical Group, Saudi German Hospital, Dubai, Fujairah Private Hospital, Al Noor Hospital Group, Lifeline Hospital Group, Al Zahra Hospital, RAK ETA Group Hospital, EMAAR Group, Moopens Group, Gulf Healthcare Pvt. Ltd, Al Khaleej Specialized Hospital &Emirates Intl-Al Ain etc.

CONTACT US : AbuDhabi Atlas Medical, PO Box: 46200, Al Masood Towers, Hamdan Street, AbuDhabi U.A.E +9712 621 7732(T), +971 2 621 6410(F) Dubai Atlas Medical, POBox: 28610, Muhaisana2, Fakurdhin Building, Dubai U.A.E +971 4 2 554522(T), +971 4 2554566(F) VISIT US E-mail:atlasmed@emirates.net.ae www.atlasmedical-uae.com

www.uaecancercongress.ae

means strengthening your patients to keep treatment on track

Variety of nutritional solutions that works in your challenging patients

www.uaecancercongress.ae

Experience Dubai

About Dubai Dubai - the exotic j jewel of the United Arab Emirates; Bordered by deserts

and beaches, Dubai provides stark contrasts, from intriguing Islamic culture to the ultra-modern, high-tech metropolis of the 21st century. The city is a magnificent expression of an incredible vision and an uncompromising statement of success and opportunity. Dubai has something for everyone, from vacationers seeking a relaxing break away from the pressures of work, to business travellers looking for a new exciting experience. The emirate is an international conference, exhibition and leisure destination. Lying on the calm, blue waters of the southern Gulf and flanked by the majestic desert, Dubai offers year-round sunshine and five-star luxury along with the adventure of a unique Arabian experience. Dubai is a class destination with all the modern amenities of the western world. It is a fascinating emirate with beautiful buildings, excellent restaurants and nightlife as well as white sandy beaches, culture and history that you can feel as you visit the souks, shopping malls, museums and historic buildings and sites.

Climate Dubai has a sub-tropical, arid climate. Sunny, blue skies can be expected most of the year. Rainfall is infrequent and irregular, falling mainly in winter. Temperatures range from a low of about 10.5°C /50 °F to a high of 48°C/118.4°F. The mean daily maximum is 24 °C/75.2 °F in January rising to 41°C/105.8 °F in July.

Clothing Lightweight summer clothing is suitable for most of the year, but sweaters or jackets may be needed for the winter months, especially in the evenings. Compared with certain parts of the Middle East, Dubai has a very relaxed dress code. However, care should be taken not to give offence by wearing clothing which may be considered revealing, for example low-cut dresses, very short skirts, or tight shirt or top in public. At the pool or on the beaches, trunks, swimsuits and bikinis are quite acceptable. Good quality sunglasses are advised, and photo chromatic lenses for those who wear spectacles. Hats, or some protection for the head, are advisable when in direct sunlight. 86

www.uaecancercongress.ae

Experience Dubai

Culture & Lifestyle Dubaiâ&#x20AC;&#x2122;s culture is firmly rooted in the Islamic traditions of Arabia. Courtesy and hospitality are among the most highly prized of virtues, and the visitor is sure to be charmed by the genuine warmth and friendliness of the people. Dubai society is marked by a high degree of tolerance for different lifestyles. Foreigners are free to practice their own religion, alcohol is served in hotels and, provided reasonable discretion is shown, the dress code is liberal. Women face no discrimination and may drive and walk around unescorted. Despite rapid economic development in recent years, Dubai remains close to its heritage. Local citizens dress in traditional robes and headdress. Arab culture and folklore find expression in poetry, dancing, songs and traditional art. Weddings and other celebrations are colourful occasions of feasting and music. Traditional sports such as falconry, camel racing and dhow racing at sea continue to thrive.

Language & Religion The official language is Arabic but English is widely spoken and understood. Both languages are commonly used in business and commerce. Islam is the official religion of the UAE and there are a large number of mosques throughout the city. Other religions are respected and Dubai has two Christian churches, St Maryâ&#x20AC;&#x2122;s (Roman Catholic) and Holy Trinity (inter-denominational).

Photography Normal tourist photography is allowed, however it is considered offensive to photograph Muslim women. It is also courteous to request permission before photographing men.

Currency The

monetary unit is the dirham which is divided into 100 fils. The dirham is linked to the Special Drawing Right of the International Monetary Fund. It has been held constant against the US dollar since the end of 1980 at a mid-rate of approximately US$1= Dh3.67.

www.uaecancercongress.ae

Experience Dubai Dubai City Tour ‘Taste of Dubai’ Pass by Jumeirah Mosque, which is a spectacular example of modern Islamic architecture and is one of the most photographed sights in Dubai. Drive past impressive Beach Palaces of Dubai Sheiks. Visit the museum which throws light on Dubai’s historical links with trading and pearl diving. Enroute we also pass by the ancient, beautifully restored house of Sheikh Saeed, the grandfather of the present Ruler of Dubai. The housed in the 180 year old Al FahidiFort, and Bastakia region which has wind towered houses, that is still standing as a reminder of the grace-full and resourceful architecture that predated the arrival of electricity and air-conditioning.

Dhow Cruise Discover the true beauty of Dubai while aboard of a traditionally decorated wooden dhow as it sails along the Dubai creek under the moonlight. It offers an intriguingly different view of the beautiful city Dubai, which is a delightful mix and match of the traditional and modern way of life. The majority of the Dubai landmarks can be viewed while on board of the dhow, splendid examples of modern architecture like the National Bank of Dubai and the spectacular Chamber of Commerce and Industry building, whilst Sheikh Saeed’s House, the birthplace of Sheikh Rashid and the Heritage Village are reminiscent of days gone by. This evening cruise includes a buffet dinner, along with soft drinks, coffee and mineral water.

www.uaecancercongress.ae

Experience Dubai Modern “Do Buy” Shopping Tour Dubai is a shopper’s paradise offering an endless choice to suit every budget. We’ll take you shopping to multi-level, world-class, air-conditioned malls where you get the latest of everything the world has to offer. Our shopping tour will take you to the following places. Souk Madinat Jumeirah - The souk is a colorful and vibrant market or part of a market in an Arabian city. Lively trading culture, animated, interactive - this defines Souk MadinatJumeirah. Dubai Mall - Is the region’s premier shopping, lifestyle and entertainment destination. With more than 1,200 stores and a host of world-class attractions, The Dubai Mall is revolutionizing the modern shopping experience. With an impressive array of leisure pursuits, this is the ultimate, cutting-edge shopping experience. A range of adventure sports vies for attention alongside the romance of ice-skating. The Dubai Mall is a place where outdoor brunch can be followed by the delights of the big screen and where a 21st century gold souk is set off against a world class Aquarium. When was the last time your sortie to the designer stores took place under the watchful eye of a giant sea turtle? Step inside The Dubai Mall and experience a place like no other. Desert Safari BBQ Dinner This tour departs in the afternoon by 4WDs across the desert of Dubai with several photo-stops during an exciting dune drive to the first destination, a camel farm. The drive continues across the desert. We stop to watch the beautiful sunset before reaching our campsite where you have the opportunity to do a camel ride, sand boarding and try out a henna design on hand or feet. Enjoy a delicious barbecue dinner and shisha (the famous Arabic water pipe). Before returning to Dubai watch our belly dancer performing her show around the campfire by starlight. This tour Includes 40 min dune drive, BBQ dinner, belly dancing, henna tattoo, camel ride, hubbly bubbly, soft drink and mineral water.

www.uaecancercongress.ae

Acnowledgement

Thank you to all our Sponsors & Exhibitors for their Support Platinum Sponsors

ONCOLOGY

Gold Sponsors

ONCOLOGY Putting progress into practice

Eisai MENA

Silver Sponsors

Support Sponsors

Exhibitors Sirtex Medical Europe GmbH.

Merck Sharp & Dohme

New Bridge Pharmaceuticals

Pierre Fabre Oncology

NeoBiocon 90

EMEACR

Oncology Nursing Society Biologix

Pure Heart

www.uaecancercongress.ae

BGICS